TWI586356B - 藉由抑制par4天然反股轉錄本治療par4相關疾病 - Google Patents
藉由抑制par4天然反股轉錄本治療par4相關疾病 Download PDFInfo
- Publication number
- TWI586356B TWI586356B TW105105551A TW105105551A TWI586356B TW I586356 B TWI586356 B TW I586356B TW 105105551 A TW105105551 A TW 105105551A TW 105105551 A TW105105551 A TW 105105551A TW I586356 B TWI586356 B TW I586356B
- Authority
- TW
- Taiwan
- Prior art keywords
- strand
- oligonucleotide
- par4
- rna
- polynucleotide
- Prior art date
Links
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 title description 138
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 50
- 238000011282 treatment Methods 0.000 title description 48
- 201000010099 disease Diseases 0.000 title description 44
- 230000005764 inhibitory process Effects 0.000 title description 7
- 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 title description 5
- 108020005544 Antisense RNA Proteins 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims description 304
- 150000007523 nucleic acids Chemical group 0.000 claims description 147
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 claims description 143
- 125000003729 nucleotide group Chemical group 0.000 claims description 141
- 239000002773 nucleotide Substances 0.000 claims description 127
- 102000039446 nucleic acids Human genes 0.000 claims description 118
- 108020004707 nucleic acids Proteins 0.000 claims description 118
- 239000002157 polynucleotide Substances 0.000 claims description 73
- 102000040430 polynucleotide Human genes 0.000 claims description 62
- 108091033319 polynucleotide Proteins 0.000 claims description 62
- 230000014509 gene expression Effects 0.000 claims description 58
- -1 phosphotriesters Chemical class 0.000 claims description 40
- 235000000346 sugar Nutrition 0.000 claims description 35
- 230000004048 modification Effects 0.000 claims description 32
- 238000012986 modification Methods 0.000 claims description 32
- 239000004055 small Interfering RNA Substances 0.000 claims description 32
- 108020004459 Small interfering RNA Proteins 0.000 claims description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 6
- 101150057630 par-4 gene Proteins 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical class NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 claims description 3
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims description 2
- 101001113471 Homo sapiens Proteinase-activated receptor 4 Proteins 0.000 claims 10
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 claims 10
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 claims 1
- GRKUXCWELVWVMZ-UHFFFAOYSA-N amino acetate Chemical class CC(=O)ON GRKUXCWELVWVMZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 150000003673 urethanes Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 151
- 230000009368 gene silencing by RNA Effects 0.000 description 139
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 134
- 108091030071 RNAI Proteins 0.000 description 123
- 210000004027 cell Anatomy 0.000 description 90
- 108090000623 proteins and genes Proteins 0.000 description 82
- 108020004999 messenger RNA Proteins 0.000 description 72
- 108020004414 DNA Proteins 0.000 description 67
- 102000053602 DNA Human genes 0.000 description 67
- 230000006870 function Effects 0.000 description 67
- 238000000034 method Methods 0.000 description 54
- 239000000203 mixture Substances 0.000 description 48
- 230000027455 binding Effects 0.000 description 29
- 230000000295 complement effect Effects 0.000 description 29
- 230000037396 body weight Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 239000002502 liposome Substances 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 25
- 239000000523 sample Substances 0.000 description 23
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 21
- 230000006907 apoptotic process Effects 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 208000011580 syndromic disease Diseases 0.000 description 19
- 108090000994 Catalytic RNA Proteins 0.000 description 18
- 102000053642 Catalytic RNA Human genes 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 18
- 108091092562 ribozyme Proteins 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 230000014616 translation Effects 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 230000002255 enzymatic effect Effects 0.000 description 17
- 150000002632 lipids Chemical group 0.000 description 17
- 108010058731 nopaline synthase Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000013519 translation Methods 0.000 description 17
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 16
- 108091081024 Start codon Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 238000003753 real-time PCR Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000008685 targeting Effects 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000002243 precursor Substances 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 229930024421 Adenine Natural products 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 13
- 241000282412 Homo Species 0.000 description 13
- 239000012097 Lipofectamine 2000 Substances 0.000 description 13
- 229960000643 adenine Drugs 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 12
- 101710163270 Nuclease Proteins 0.000 description 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 9
- 230000003460 anti-nuclear Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 229940104302 cytosine Drugs 0.000 description 9
- 229920000768 polyamine Polymers 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000013603 viral vector Substances 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 230000014621 translational initiation Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 108700011259 MicroRNAs Proteins 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 230000004700 cellular uptake Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 229940113082 thymine Drugs 0.000 description 6
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- 108091092724 Noncoding DNA Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 241000251131 Sphyrna Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 150000004713 phosphodiesters Chemical class 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 4
- 208000001089 Multiple system atrophy Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 230000007022 RNA scission Effects 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 108091060271 Small temporal RNA Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 102000039634 Untranslated RNA Human genes 0.000 description 4
- 108020004417 Untranslated RNA Proteins 0.000 description 4
- 201000004810 Vascular dementia Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 206010008129 cerebral palsy Diseases 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 150000003017 phosphorus Chemical class 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 3
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 3
- 102000010170 Death domains Human genes 0.000 description 3
- 108050001718 Death domains Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 3
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 201000007201 aphasia Diseases 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000003633 gene expression assay Methods 0.000 description 3
- 125000003827 glycol group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000011880 melting curve analysis Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical group C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 2
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 2
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 2
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002941 Apallic syndrome Diseases 0.000 description 2
- 101100465057 Arabidopsis thaliana PRK2 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003101 Arnold-Chiari Malformation Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010048409 Brain malformation Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000015321 Chiari malformation Diseases 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000938605 Crocodylia Species 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical group OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Chemical group OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Chemical group OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108020005350 Initiator Codon Proteins 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Chemical group CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 208000026072 Motor neurone disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 206010061533 Myotonia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229910004679 ONO2 Inorganic materials 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 208000005587 Refsum Disease Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- RLXCFCYWFYXTON-JTTSDREOSA-N [(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] N-hexylcarbamate Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC(=O)NCCCCCC)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLXCFCYWFYXTON-JTTSDREOSA-N 0.000 description 2
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000000252 angiomatosis Diseases 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000012056 cerebral malformation Diseases 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- GTZOYNFRVVHLDZ-UHFFFAOYSA-N dodecane-1,1-diol Chemical group CCCCCCCCCCCC(O)O GTZOYNFRVVHLDZ-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 208000004343 lateral medullary syndrome Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 208000005026 persistent vegetative state Diseases 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical group C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FQQQSNAVVZSYMB-UHFFFAOYSA-N 1,1-diaminoguanidine Chemical compound NN(N)C(N)=N FQQQSNAVVZSYMB-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
- BRLJKBOXIVONAG-UHFFFAOYSA-N 2-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl-methylamino]acetic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(C)CC(O)=O BRLJKBOXIVONAG-UHFFFAOYSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- XIFVTSIIYVGRHJ-UHFFFAOYSA-N 2-n,2-n,4-n,4-n,6-n-pentamethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N(C)C)=NC(N(C)C)=N1 XIFVTSIIYVGRHJ-UHFFFAOYSA-N 0.000 description 1
- YNFSUOFXEVCDTC-UHFFFAOYSA-N 2-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=C2NC=NC2=N1 YNFSUOFXEVCDTC-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Chemical group C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000024341 Aicardi syndrome Diseases 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- 208000036022 Alpers' disease Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 208000022316 Arachnoid cyst Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000796533 Arna Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
- 206010006074 Brachial plexus injury Diseases 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010006491 Brown-Sequard syndrome Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DZIPPJPLPPBOHM-JZIBRUIUSA-N C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1.C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1.C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 DZIPPJPLPPBOHM-JZIBRUIUSA-N 0.000 description 1
- 101100181137 Caenorhabditis elegans pkc-3 gene Proteins 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SRBFZHDQGSBBOR-AGQMPKSLSA-N D-lyxopyranose Chemical compound O[C@@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-AGQMPKSLSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100269980 Drosophila melanogaster aPKC gene Proteins 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014567 Empty Sella Syndrome Diseases 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000007223 Gerstmann syndrome Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 206010061199 Head deformity Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 206010022158 Injury to brachial plexus due to birth trauma Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 201000008645 Joubert syndrome Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 208000006541 Klippel-Feil syndrome Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000428198 Lutrinae Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 201000002983 Mobius syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 208000020265 O'Sullivan-McLeod syndrome Diseases 0.000 description 1
- KRIMDSNQQXJAIF-UHFFFAOYSA-N OP(O)(=O)ON=C=S Chemical class OP(O)(=O)ON=C=S KRIMDSNQQXJAIF-UHFFFAOYSA-N 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 241000282943 Odocoileus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 108700043304 PKC-3 Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010052469 Postictal paralysis Diseases 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 108091029810 SaRNA Proteins 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000021235 Schilder disease Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 201000003696 Sotos syndrome Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical group CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-KCDKBNATSA-N aldehydo-L-fucose Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-KCDKBNATSA-N 0.000 description 1
- PYMYPHUHKUWMLA-YUPRTTJUSA-N aldehydo-L-lyxose Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-YUPRTTJUSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940037157 anticorticosteroids Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 201000006431 brachial plexus neuropathy Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000003340 combinatorial analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 210000004714 cranial suture Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 108700007153 dansylsarcosine Proteins 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- GPRLSGONYQIRFK-DYCDLGHISA-N deuteron Chemical compound [2H+] GPRLSGONYQIRFK-DYCDLGHISA-N 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- VUSHQLWDOJFSGF-UHFFFAOYSA-L disodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate chloride Chemical compound [Na+].[Na+].Cl.[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O VUSHQLWDOJFSGF-UHFFFAOYSA-L 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- DLKYYJFLRUUGHJ-SSJCJZGYSA-A fomivirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([S-])(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DLKYYJFLRUUGHJ-SSJCJZGYSA-A 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 208000021245 head disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229950000547 mafosfamide Drugs 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- GZCNJTFELNTSAB-UHFFFAOYSA-N n'-(7h-purin-6-yl)hexane-1,6-diamine Chemical compound NCCCCCCNC1=NC=NC2=C1NC=N2 GZCNJTFELNTSAB-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical group N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000010450 olivine Substances 0.000 description 1
- 229910052609 olivine Inorganic materials 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000005877 painful neuropathy Diseases 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 208000029308 periodic paralysis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000002477 septooptic dysplasia Diseases 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-O trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=[NH+]C(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-O 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
本發明實施例包括調節PAR4及有關分子之表現及/或功能之寡核苷酸。
本申請案主張2010年5月14日提出申請之美國臨時專利申請案第61/334,933號之優先權,其全部內容以引用方式併入本文中。
DNA-RNA及RNA-RNA雜交對核酸功能之許多態樣(包含DNA複製、轉錄、及轉譯)較為重要。雜交對於檢測特定核酸或改變其表現之各種技術亦甚為重要。舉例而言,反股核苷酸藉由與靶RNA雜交、由此干擾RNA剪接、轉錄、轉譯、及複製來破壞基因表現。反股DNA具有額外特徵,亦即DNA-RNA雜合體用作核糖核酸酶H消化之受質,該活性存在於大部分細胞類型中。反股分子可遞送至細胞中,如寡去氧核苷酸(ODN)之情形,或其可自內源基因表現為RNA分子。FDA最近批准了反股藥物VITRAVENETM(用於治療巨細胞病毒視網膜炎),此表明該反股藥物具有治療用途。
提供本概述以呈現本發明之概述從而簡要顯示本發明之性質及物質。提交本概述係基於下列理解:其並非用於解釋或限制本申請專利範圍之範圍或含義。
在一實施例中,本發明提供抑制天然反股轉錄本之作用之方法,其係藉由使用靶向天然反股轉錄本之任一區域的反股寡核苷酸從而上調相應正股基因來達成。本文亦涵蓋,可藉由siRNA、核糖酶及小分子來抑制天然反股轉錄本,此視為屬於本發明範圍內。
一實施例提供在活體內或活體外調節患者細胞或組織中PAR4多核苷酸之功能及/或表現之方法,其包括使該等細胞或組織與長度為5至30個核苷酸之反股寡核苷酸接觸,其中該寡核苷酸與多核苷酸之反向互補體具有至少50%之序列一致性,該多核苷酸包括SEQ ID NO:2中核苷酸1至354內之5至30個連續核苷酸,由此在活體內或活體外調節患者細胞或組織中PAR4多核苷酸之功能及/或表現。
在一實施例中,寡核苷酸靶向PAR4多核苷酸之天然反股序列(例如,SEQ ID NO:2中所述之核苷酸)、及其任一變體、等位基因、同系物、突變體、衍生物、片段及互補序列。將反股寡核苷酸之實例闡述為SEQ ID NO:3至9。
另一實施例提供在活體內或活體外調節患者細胞或組織中PAR4多核苷酸之功能及/或表現之方法,其包括使該等細胞或組織與長度為5至30個核苷酸之反股寡核苷酸接觸,其中該寡核苷酸與PAR4多核苷酸反股轉錄本之反向互補體具有至少50%的序列一致性;由此在活體內或活體外調節患者細胞或組織中PAR4多核苷酸之功能及/或表現。
另一實施例提供在活體內或活體外調節患者細胞或組織中PAR4多核苷酸之功能及/或表現之方法,其包括使該等細胞或組織與長度為5至30個核苷酸之反股寡核苷酸接觸,其中該寡核苷酸與PAR4反股多核苷酸之反股寡核苷酸具有至少50%的序列一致性;由此在活體內或活體外調節患者細胞或組織中PAR4多核苷酸之功能及/或表現。
在一實施例中,組合物包括一或多個結合至正股及/或反股PAR4
多核苷酸之反股寡核苷酸。
在一實施例中,寡核苷酸包括一或多個經修飾或取代之核苷酸。
在一實施例中,寡核苷酸包括一或多個經修飾鍵。
在又一實施例中,經修飾核苷酸包括含有以下之經修飾鹼基:硫代磷酸酯、膦酸甲酯、肽核酸、2'-O-甲基、氟-或碳、亞甲基或其他鎖核酸(LNA)分子。較佳地,經修飾核苷酸係鎖核酸分子,包含α-L-LNA。
在一實施例中,經皮下、肌內、靜脈內或腹膜腔內將寡核苷酸投與患者。
在一實施例中,以醫藥組合物形式投與寡核苷酸。治療方案包括向患者投與反股化合物至少一次;然而,此治療可經修飾以在一定時間內包含多個劑量。該治療可與一或多個其他類型之療法組合。
在一實施例中,將寡核苷酸囊封於脂質體中或附接至載劑分子(例如膽固醇、TAT肽)。
其他態樣闡述於下文中。
圖1展示與對照相比,在使用利用Lipofectamine 2000引入之硫代磷酸酯寡聚物處理後48小時時,HepG2細胞中PAR4 mRNA之變化倍數及標準偏差。實時PCR結果顯示,在使用兩種設計為PAR4反股jortybo.aApr07之寡聚物處理後48h時,HepG2細胞中之PAR4 mRNA之含量顯著增加。表示為CUR-1564至CUR-1570之條形分別對應於使用SEQ ID NO:3至9處理之試樣。
圖2展示與對照相比,在使用利用Lipofectamine 2000引入之硫代磷酸酯寡聚物處理後48小時時,A549細胞中PAR4 mRNA之變化倍數及標準偏差。實時PCR結果顯示,在使用設計為PAR4反股
jortybo.aApr07之寡CUR-1566處理後48h時,A459細胞中之PAR4 mRNA含量顯著增加。表示為CUR-1566之條形對應於使用SEQ ID NO:5處理之試樣。
圖3展示與對照相比,在使用利用Lipofectamine 2000引入之CUR-1566處理後48小時時,HEK293細胞中細胞凋亡之增加。表示為CUR-1566之條形對應於使用SEQ ID NO:5處理之試樣。
圖4展示與對照相比,在使用利用Lipofectamine 2000引入之CUR-1566處理後48小時時,角質形成細胞中之細胞凋亡有所增加。表示為CUR-1566之條形對應於使用SEQ ID NO:5處理之試樣。
圖5展示與對照相比,在使用利用Lipofectamine 2000引入之硫代磷酸酯寡聚物處理後48小時時,HepG2細胞中細胞凋亡之增加。表示為CUR-1565、CUR-1566及CUR-1568之條形對應於使用SEQ ID NO:4、5及7處理之試樣。
圖6展示與對照相比,在使用利用Lipofectamine 2000引入之CUR-1566處理後48小時時,MCF-7細胞中細胞凋亡之增加。表示為CUR-1565、CUR-1566及CUR-1568之條形對應於使用SEQ ID NO:4、5及7處理之試樣。
序列表說明-SEQ ID NO:1:智人(Homo sapiens)PRKC,細胞凋亡,WT1,調節劑(PAWR),mRNA(NCBI登錄號:NM_002583);SEQ ID NO:2:天然PAR4反股序列(jortybo.aApr07);SEQ ID NO:3至9:反股寡核苷酸。*表示硫代磷酸酯鍵。
下文參照闡釋用實例應用來闡述本發明之若干態樣。應理解,本文列舉各種具體細節、關係及方法以提供對本發明之完全理解。然而,熟習相關技術者易於認識到,可在不使用一或多個具體細節或使用其他方法之情形下來實踐本發明。本發明並不限於各個動作或事件
之順序,此乃因一些作用可以不同順序發生及/或與其他動作或事件同時發生。另外,未必需要所有所闡釋動作或事件來實施本發明方法。
本文所揭示所有基因、基因名稱、及基因產物意欲對應於可應用本文所揭示組合物及方法之來自任一物種的同系物。因此,該等術語包含但不限於人類及小鼠之基因及基因產物。應理解,在揭示來自特定物種之基因或基因產物時,除非在上下文中明確指出,否則此揭示內容意欲僅具有實例性,且不應解釋為限制意義。因此,舉例而言,對於在一些實施例中係關於哺乳動物核酸及胺基酸序列之本文所揭示基因而言,其意欲涵蓋來自其他動物之同源及/或直系同源基因及基因產物,該等其他動物包含但不限於其他哺乳動物、魚、兩棲動物、爬行動物、及鳥。在一實施例中,基因或核酸序列係人類。
本文所用之術語僅用於闡述特定實施例之目的而並非意欲限定本發明。如本文中所使用,單數形式「一(a)」、「一(an)」及「該(the)」亦意欲包含複數形式,除非上下文另外明確指明。另外,在詳細闡述及/或申請專利範圍中使用術語「包含(including)」、「包含(includes)」、「具有(having)」、「具有(has)」、「具有(with)」、或其變化形式時,該等術語意欲以類似於術語「包括(comprising)」之方式來表示包含範圍。
術語「約」或「近似地」意指熟習此項技術者所測定之特定值的可接受誤差範圍,其部分地取決於該值之量測或測定方式,亦即,量測系統之侷限性。舉例而言,根據業內實踐,「約」可意指在1個或1個以上之標準偏差內。另一選擇為,「約」可意指與給定值相差至多20%、較佳至多10%、更佳至多5%、及更佳至多1%的範圍。另一選擇為,尤其對於生物系統或過程而言,該術語可意指在一數值之一個
數量級內、較佳在5倍內、及更佳在2倍內。在申請案及申請專利範圍中闡述特定值時,除非另有闡述,否則應假設術語「約」意指在該特定值之可接受誤差範圍內。
本文所用之術語「mRNA」意指靶向基因之當前已知mRNA轉錄本、及可闡釋之任一其他轉錄本。
「反股寡核苷酸」或「反股化合物」意指結合至另一RNA或DNA(靶RNA、DNA)之RNA或DNA分子。舉例而言,若係RNA寡核苷酸,則其藉助RNA-RNA相互作用結合至另一RNA靶並改變靶RNA之活性。反股寡核苷酸可上調或下調特定多核苷酸之表現及/或功能。該定義意欲包含可用於治療、診斷、或其他方面之任一外來RNA或DNA分子。該等分子包含(例如)反股RNA或DNA分子、干擾RNA(RNAi)、微小RNA、誘餌RNA分子、siRNA、酶RNA、治療性編輯RNA及RNA激動劑與拮抗劑、反股寡聚化合物、反股寡核苷酸、外部引導序列(EGS)寡核苷酸、交替剪接、引物、探針、及與靶核酸之至少一部分雜交之其他寡聚化合物。因此,該等化合物可以單鏈、雙鏈、部分單鏈、或環狀寡聚化合物形式引入。
在本發明之上下文中,術語「寡核苷酸」係指核糖核酸(RNA)或去氧核糖核酸(DNA)之寡聚物或聚合物或其模擬物。術語「寡核苷酸」亦包含天然及/或經修飾單體或鍵聯之直鏈或環狀寡聚物,包含去氧核糖核苷、核糖核苷、其經取代及α-變旋異構形式、肽核酸(PNA)、鎖核酸(LNA)、硫代磷酸酯、膦酸甲酯、及諸如此類。寡核苷酸能夠藉助單體與單體相互作用之規則模式特異性結合至靶多核苷酸,例如Watson-Crick型鹼基配對、Hoögsteen型鹼基配對或反向Hoögsteen型鹼基配對、或諸如此類。
寡核苷酸可為「嵌合」寡核苷酸,亦即,由不同區域組成。在本發明之上下文中,「嵌合」化合物係寡核苷酸,其含有兩個或更多
個化學區域,例如DNA區域、RNA區域、PNA區域等。在寡核苷酸化合物之情形下,每一化學區域係由至少一個單體單元(亦即,核苷酸)組成。該等寡核苷酸通常包括至少一個對寡核苷酸進行修飾以顯示一或多個期望性質之區域。寡核苷酸之期望性質包含但不限於(例如):增加對於核酸酶降解之抗性、增加細胞攝取、及/或增加對於靶核酸之結合親和力。寡核苷酸之不同區域可由此具有不同性質。本發明之嵌合寡核苷酸可形成為兩種或更多種上述寡核苷酸、經修飾寡核苷酸、寡核苷及/或寡核苷酸類似物的混合結構。
寡核苷酸可由可在「記錄(register)」中連接之區域組成,亦即,單體係連續連接(如天然DNA中)、或經由間隔體連接。間隔體意欲在區域之間構成共價「橋」且在較佳情形下具有不超過約100個碳原子之長度。間隔體可具有不同功能,例如具有正電荷或負電荷,具有特異性核酸結合性質(嵌合劑、槽溝黏合劑、毒素、螢光團等),具有親脂性,誘導特異性二級結構(例如,誘導α螺旋之含丙胺酸肽)。
本文所用之「PAR4」及「Par-4」包含所有家族成員、突變體、等位基因、片段、物種、編碼及非編碼序列、正股及反股多核苷酸鏈等。
本文所用之詞語PAR4、par-4、Par-4、PRKC細胞凋亡WT1調節蛋白、前列腺細胞凋亡反應4蛋白在文獻中皆視為相同且在本申請案中可互換使用。
本文所用之術語「對…具有特異性之寡核苷酸」或「靶向…之寡核苷酸」係指具有如下序列之寡核苷酸:(i)能夠與靶向基因之一部分形成穩定複合物,或(ii)能夠與靶向基因之mRNA轉錄本的一部分形成穩定雙鏈體。複合物及雙鏈體之穩定性可藉由理論計算及/或活體外分析進行測定。測定雜交複合物及雙鏈體之穩定性的實例性分析闡述於下文實例中。
本文所用之術語「靶核酸」涵蓋自該DNA轉錄之DNA、RNA(包括mRNA前體及mRNA)、以及源自該RNA、編碼序列、非編碼序列、正股或反股多核苷酸之cDNA。寡聚化合物與其靶核酸之特異性雜交會干擾該核酸之正常功能。與靶核酸特異性雜交之化合物對該靶核酸功能的此調節通常稱為「反股」。擬干擾之DNA功能包含(例如)複製及轉錄。擬干擾之RNA功能包含所有重要功能,例如,RNA至蛋白質轉譯位點之異位、蛋白質自RNA之轉譯、使RNA產生一或多種mRNA物質之剪接、及RNA可參與或促進之催化活性。對於靶核酸功能之該干擾的總體效應係可調節編碼產物或寡核苷酸之表現。
RNA干擾(「RNAi」)係藉由與「靶」核酸序列具有序列特異性同源性之雙鏈RNA(dsRNA)分子來調介。在本發明某些實施例中,介質係具有5-25個核苷酸之「小干擾」RNA雙鏈體(siRNA)。siRNA源自稱為Dicer之RNase酶對於dsRNA之處理。siRNA雙鏈體產物募集至稱為RISC之多蛋白siRNA複合物(RNA誘導之沉默複合物)中。不期望受限於任一特定理論,由此據信,RISC可引導至靶核酸(mRNA較為適宜),在此siRNA雙鏈體以序列特異性方式發生相互作用從而以催化方式來調介裂解。可用於本發明中之小干擾RNA可根據業內所熟知且為熟習此項技術者所習知的程序來合成及使用。用於本發明方法中之小干擾RNA適宜地包括約1至約50個核苷酸(nt)。在非限制性實施例之實例中,siRNA可包括約5至約40個nt、約5至約30個nt、約10至約30個nt、約15至約25個nt、或約20-25個核苷酸。
藉由使用自動對凖核酸序列並指示一致性或同源性區域之電腦程式來促進適當寡核苷酸的選擇。使用該等程式藉由(例如)搜索諸如GenBank等數據庫或藉由對PCR產物測序來比較所獲得的核酸序列。對於來自各種物種之核酸序列之比較使得可選擇顯示適當物種間一致性程度的核酸序列。在並未測序之基因情形下,實施南方印跡
(Southern blot)以測定靶物種及其他物種之基因間的一致性程度。藉由在不同嚴格度下實施南方印跡(如業內所熟知),可大致量測一致性。該等程序使得可選擇如下寡核苷酸:其對欲控制個體中之靶核酸序列呈現高互補性程度且對其他物種中之相應核酸序列呈現較低互補性程度。熟習此項技術者應認識到,可在較大範圍中選擇適用於本發明中之基因區域。
「酶RNA」意指具有酶活性之RNA分子(Cech,(1988)J.American.Med.Assoc.260,3030-3035)。酶性核酸(核酶)首先藉由結合至靶RNA而發揮作用。該結合經由酶性核酸之靶結合部分來進行,該靶結合部分緊鄰分子中用於裂解靶RNA之酶性部分。因此,酶性核酸首先識別靶RNA且然後經由鹼基配對與靶RNA結合,且在結合至確切位點後以酶促方式發揮作用以切割靶RNA。
「誘餌RNA」意指模擬配體之天然結合結構域之RNA分子。誘餌RNA由此與天然結合靶競爭結合特異性配體。舉例而言,已顯示HIV反式活化反應(TAR)RNA之過度表現可用作「誘餌」並有效結合HIV tat蛋白,由此預防其結合至在HIV RNA中編碼之TAR序列。此意欲係一具體實例。彼等熟習此項技術者應認識到,此僅為一實例,且可易於使用業內通常已知之技術來產生其他實施例。
本文所用之術語「單體」通常表示藉由磷酸二酯鍵或其類似物連接以形成尺寸介於數個單體單元(例如,約3-4個)至約數百個單體單元之寡核苷酸的單體。磷酸二酯鍵聯之類似物包含:硫代磷酸酯、二硫代磷酸酯、膦酸甲酯、硒代磷酸酯、胺基磷酸酯、及諸如此類,如下文更全面所述。
術語「核苷酸」涵蓋天然存在之核苷酸以及非天然存在之核苷酸。熟習此項技術者應明瞭,先前視為「非天然存在」之各種核苷酸後來已發現於自然界中。因此,「核苷酸」不僅包含含有已知嘌呤及
嘧啶雜環之分子,且亦包含其雜環類似物及互變異構體。其他類型核苷酸之闡釋性實例係含有以下部分之分子:腺嘌呤、鳥嘌呤、胸腺嘧啶、胞嘧啶、尿嘧啶、嘌呤、黃嘌呤、二胺基嘌呤、8-側氧基-N6-甲基腺嘌呤、7-去氮黃嘌呤、7-去氮鳥嘌呤、N4,N4-乙醇胞嘧啶、N6,N6-乙醇-2,6-二胺基嘌呤、5-甲基胞嘧啶、5-(C3-C6)-炔基胞嘧啶、5-氟尿嘧啶、5-溴尿嘧啶、假異胞嘧啶、2-羥基-5-甲基-4-三唑并吡啶、異胞嘧啶、異鳥嘌呤、肌苷及Benner等人之美國專利第5,432,272號中所述之「非天然存在」核苷酸。術語「核苷酸」意欲涵蓋每一及所有該等實例以及其類似物及互變異構體。尤其關注之核苷酸係彼等含有腺嘌呤、鳥嘌呤、胸腺嘧啶、胞嘧啶、及尿嘧啶者,其係視為與人類之治療及診斷應用有關之天然存在之核苷酸。核苷酸包含天然2'-去氧及2'-羥基糖(例如,如Kornberg及Baker,DNA Replication,第2版(Freeman,San Francisco,1992)中所述)以及其類似物。
涉及核苷酸之「類似物」包含具有經修飾鹼基部分及/或經修飾糖部分之合成核苷酸(參見(例如)由以下所概述:Scheit,Nucleotide Analogs,John Wiley,New York,1980;Freier & Altmann,(1997)Nucl.Acid.Res.,25(22),4429-4443,Toulmé,J.J.,(2001)Nature Biotechnology 19:17-18;Manoharan M.,(1999)Biochemica et Biophysica Acta 1489:117-139;Freier S.M.,(1997)Nucl.Acid Research,25:4429-4443,Uhlman,E.,(2000)Drug Discovery & Development,3:203-213,Herdewin P.,(2000)Antisense & Nucleic Acid Drug Dev.,10:297-310);2'-O、3'-C連接之[3.2.0]雙環阿糖核苷。該等類似物包含經設計以增強結合性質(例如,雙鏈體或三鏈體穩定性、特異性、或諸如此類)之合成核苷酸。
本文所用之「雜交」意指寡聚化合物之實質上互補鏈之配對。
一種配對機制涉及寡聚化合物鏈之互補核苷或核苷酸鹼基(核苷酸)之間的氫鍵,其可為Watson-Crick、Hoögsteen或反向Hoögsteen氫鍵。舉例而言,腺嘌呤及胸腺嘧啶係經由形成氫鍵配對之互補核苷酸。雜交可在不同情形下發生。
在以下情形時反股化合物係「可特異性雜交」:化合物與靶核酸之結合可干擾靶核酸之正常功能以調節功能及/或活性,且存在足夠互補性程度以避免反股化合物與非靶核酸序列在期望發生特異性結合之條件下(亦即,在活體內分析或治療性治療情形中之生理條件下,及在活體外分析情形中實施分析之條件下)發生非特異性結合。
本文所用之片語「嚴格雜交條件」或「嚴格條件」係指本發明化合物與其靶序列發生雜交、但與最少數量之其他序列發生雜交的條件。嚴格條件具有序列依賴性且在不同情況及本發明上下文中有所不同,藉由寡聚化合物之性質及組成及研究其之分析來測定寡聚化合物與靶序列進行雜交的「嚴格條件」。一般而言,嚴格雜交條件包括低濃度(<0.15M)含有無機陽離子(例如Na++或K++)之鹽(亦即,低離子強度),溫度高於20℃-25℃但低於寡聚化合物:靶序列複合物之Tm,及存在變性劑(例如甲醯胺、二甲基甲醯胺、二甲基亞楓)或洗滌劑十二烷基硫酸鈉(SDS)。舉例而言,對於每一1%甲醯胺而言,雜交速率降低1.1%。高嚴格度雜交條件之實例係0.1X氯化鈉-檸檬酸鈉緩衝液(SSC)/0.1%(w/v)SDS(在60℃下,保持30分鐘)。
本文所用之「互補」係指一個或兩個寡聚鏈上之兩個核苷酸之間精確配對的能力。舉例而言,若反股化合物某一位置處之核鹼基能夠與靶核酸(該靶核酸係DNA、RNA、或寡核苷酸分子)某一位置處之核鹼基發生氫鍵結,則該寡核苷酸及該靶核酸之間發生氫鍵結之位置視為互補位置。在每一分子中有足夠數量之互補位置由可彼此氫鍵結之核苷酸佔據時,寡聚化合物及其他DNA、RNA、或寡核苷酸分子彼
此互補。因此,「可特異性雜交」及「互補」係用於指示以下情形之術語:足夠數量之核苷酸中具有足夠程度之精確配對或互補性從而寡聚化合物及靶核酸之間發生穩定及特異性結合。
業內應理解,寡聚化合物序列無需與擬特異性雜交之其靶核酸序列100%互補。另外,寡核苷酸可在一或多個區段中雜交從而插入或相鄰區段並不參與雜交事件(例如,環路結構、失配或髮夾結構)。本發明寡聚化合物包括與其所靶向靶核酸序列內靶區域之至少約70%、或至少約75%、或至少約80%、或至少約85%、或至少約90%、或至少約95%、或至少約99%的序列互補性。舉例而言,反股化合物之20個核苷酸中有18個與靶區域互補且由此特異性雜交之反股化合物將代表90%的互補性。在此實例中,剩餘非互補核苷酸可與互補核苷酸群集或散開且無需彼此鄰近或與互補核苷酸鄰近。因此,長度為18個核苷酸且具有4(四)個非互補核苷酸(由兩個與靶核酸完整互補之區域側接)之反股化合物與靶核酸具有77.8%之總體互補性且由此屬於本發明範圍內。具有靶核酸區域之反股化合物的互補性百分比通常可使用業內已知之BLAST程式(鹼基局部對凖檢索工具)及PowerBLAST程式測得。同源性、序列一致性或互補性百分比可藉由(例如)Gap程式(Wisconsin Sequence Analysis Package,Version 8 for Unix,Genetics Computer Group,University Research Park,Madison Wis.)使用默認設置(其使用Smith及Waterman算法)測得(Adv.Appl.Math.,(1981)2,482-489)。
本文所用之術語「熱力學熔點(Tm)」係指在界定離子強度、pH、及核酸濃度下與靶序列互補之寡核苷酸中之50%在平衡下與靶序列雜交的溫度。通常,對於短寡核苷酸(例如,具有10至50個核苷酸)而言,嚴格條件係彼等以下條件:鹽濃度在pH 7.0至8.3下為至少約0.01至1.0M之Na離子濃度(或其他鹽)且溫度為至少約30℃。嚴格條件
亦可藉由添加諸如甲醯胺等去穩定劑來達成。
本文所用之「調節」意指增加(刺激)或降低(抑制)基因之表現。
在用於多核苷酸序列之背景中時,術語「變體」可涵蓋與野生型基因有關之多核苷酸序列。此定義亦可包含(例如)「等位基因」、「剪接」、「物種」或「多態性」變體。剪接變體可與參考分子具有顯著一致性,但在mRNA處理期間因外顯子之交替剪接而通常具有較大或較小數量之多核苷酸。相應多肽可擁有額外功能結構域或不存在結構域。物種變體係在物種之間有所變化之多核苷酸序列。在本發明中尤其有用者係野生型基因產物之變體。變體可源自核酸序列中之至少一個突變,且可產生改變之mRNA或產生結構或功能可改變或不改變的多肽。任一給定天然或重組基因可不具有等位基因形式、具有一種或許多等位基因形式。產生變體之常見突變變化通常歸因於核苷酸之天然缺失、添加、或取代。該等變化類型中之每一者可在給定序列中單獨、或與其他者組合發生一或多次。
所得多肽通常彼此之間具有顯著之胺基酸一致性。多態性變體係給定物種個體間特定基因之多核苷酸序列中的變化。多態性變體亦可涵蓋「單一核苷酸多態性」(SNP)或單鹼基突變,其中多核苷酸序列之一個鹼基有所變化。SNP之存在可指示(例如)某一群體具有疾病狀態傾向(亦即相對於抗性之易感性)。
衍生多核苷酸包含經受化學修飾(例如,氫由烷基、醯基、或胺基代替)之核酸。衍生物(例如,衍生寡核苷酸)可包括非天然存在之部分,例如改變之糖部分或糖間鍵聯。該等實例性衍生物係硫代磷酸酯及業內已知之其他含硫物質。衍生核酸亦可含有標記,包含放射性核苷酸、酶、螢光劑、化學發光劑、發色劑、受質、輔因子、抑制劑、磁性顆粒、及諸如此類。
「衍生」多肽或肽係(例如)藉由以下方式進行修飾者:糖基化、
聚乙二醇化、磷醯化、硫酸化、還原/烷基化、醯基化、化學偶合、或輕度福爾馬林(formalin)處理。衍生物亦可經修飾以含有可檢測標記(直接或間接),包含但不限於放射性同位素、螢光、及酶標記。
本文所用之術語「動物」或「患者」意欲包含(例如)人類、綿羊、麋鹿、鹿、長耳鹿、水貂、哺乳動物、猴子、馬、牛、豬、山羊、狗、貓、大鼠、小鼠、鳥、雞、爬行動物、魚、昆蟲及蜘蛛。
「哺乳動物」涵蓋通常處於醫學護理下之溫血哺乳動物(例如,人類及家養動物)。實例包含貓、犬、馬、牛、及人類、以及僅指人類。
「治療(treating或treatment)」涵蓋對哺乳動物之疾病狀態之治療,且包含:(a)在哺乳動物中、特定而言在該哺乳動物易患有疾病狀態但尚未被診斷出患有該疾病狀態時預防該疾病狀態發生;(b)抑制疾病狀態,例如阻止其發展;及/或(c)減緩疾病狀態,例如使疾病狀態減退直至達到期望端點為止。治療亦包含改善疾病症狀(例如,減輕疼痛或不適),其中該改善可直接影響或可能並不直接影響疾病(例如,起因、傳染、表現等)。
本文所用之「癌症」係指在哺乳動物中發現之所有類型癌症或贅瘤或惡性腫瘤,其包含但不限於:白血病、淋巴瘤、黑素瘤、癌及肉瘤。癌症自身表現為包括癌症之惡性細胞之「腫瘤」或組織。腫瘤之實例包含肉瘤及癌,例如但不限於:纖維肉瘤、黏液肉瘤、脂肪肉瘤、軟骨肉瘤、成骨性肉瘤、脊索瘤、血管肉瘤、內皮肉瘤、淋巴管肉瘤、淋巴管內皮肉瘤、滑膜瘤、間皮瘤、尤因氏腫瘤(Ewing's tumor)、平滑肌肉瘤、橫紋肌肉瘤、結腸癌、胰腺癌、乳癌、卵巢癌、前列腺癌、鱗狀細胞癌、基底細胞癌、腺癌、汗腺癌、皮脂腺癌、乳頭狀癌、乳頭狀腺癌、囊腺癌、髓樣癌、枝氣管原癌、腎細胞癌、肝細胞瘤、膽管癌、絨毛膜癌、精原細胞瘤、胚胎性癌、維爾姆
斯氏腫瘤(Wilms' tumor)、宮頸癌、睪丸腫瘤、肺癌、小細胞肺癌、膀胱癌、上皮癌、膠質瘤、星形細胞瘤、髓母細胞瘤、顱咽管瘤、室管膜瘤、松果體瘤、血管母細胞瘤、聽神經瘤、少突神經膠質瘤、腦膜瘤、黑素瘤、神經母細胞瘤、及視網膜母細胞瘤。可藉由本發明所揭示組合物治療之額外癌症包含但不限於(例如)霍奇金氏病(Hodgkin's Disease)、非霍奇金氏淋巴瘤(Non-Hodgkin's Lymphoma)、多發性骨髓瘤、神經母細胞瘤、乳癌、卵巢癌、肺癌、橫紋肌肉瘤、原發性血小板增多症、原發性巨球蛋白血症、小細胞肺腫瘤、原發性腦腫瘤、胃癌、結腸癌、惡性胰腺胰島素瘤、惡性類癌、膀胱癌、胃癌、惡化前皮膚損傷、睪丸癌、淋巴瘤、甲狀腺癌、神經母細胞瘤、食管癌、泌尿生殖道癌症、惡性高鈣血症、宮頸癌、子宮內膜癌症、腎上腺皮質癌症、及前列腺癌。術語「細胞凋亡」意指程式性細胞死亡。其亦意指「細胞死亡」或「靶向細胞死亡」,其發生於投與本文所述反股寡核苷酸以治療或減輕與未控制細胞生長及/或正常細胞凋亡及/或細胞凋亡路徑功能失常有關之疾病或病症的情形下。
本文所用之「神經疾病或病症」係指神經系統及/或視覺系統之任一疾病或病症。「神經疾病或病症」包含涉及中樞神經系統(腦、腦幹及小腦)、周邊神經系統(包含顱神經)、及自主神經系統(位於中樞及周邊神經系統二者中之部分)之疾病或病症。神經疾病或病症包含但不限於後天性癲癇失語症;急性播散性腦脊髓炎;腎上腺腦白質營養不良;老年性黃斑退化症;胼胝體發育不全;失認症;艾卡迪症候群(Aicardi syndrome);亞歷山大病(Alexander disease);阿爾珀斯病(Alpers' disease);交叉性肢體癱瘓;阿爾茨海默氏病(Alzheimer's disease);血管性癡呆;肌萎縮側索硬化;無腦畸形;天使症候群(Angelman syndrome);血管瘤病;缺養症;失語症;失用症;蛛網膜囊腫;蛛網膜炎;阿-蔡二氏畸形(Anronl-Chiari malformation);動靜
脈畸形;阿斯佩格症候群(Asperger syndrome);運動失調性毛細血管擴張症;注意力缺陷伴多動病症;自閉症;自主神經功能障礙;背痛;巴登氏病(Batten disease);貝切特氏病(Behcet's disease);貝爾麻痺(Bell's palsy);良性本質瞼痙攣;良性局部肌萎縮;良性顱內高壓;賓斯旺格病(Binswanger's disease);眼瞼痙攣;布洛克-蘇茲貝克症候群(Bloch Sulzberger syndrome);臂叢神經損傷;腦膿腫;腦損傷;腦腫瘤(包含多形性膠質母細胞瘤);脊髓腫瘤;布朗-塞卡爾症候群(Brown-Sequard syndrome);卡納萬病(Canavan disease);腕道症候群;灼性神經痛;中樞性疼痛症候群;腦橋中央髓鞘溶解;頭部病症;腦動脈瘤;腦動脈硬化症;大腦萎縮;大腦性巨人症;大腦性麻痺;夏-馬-圖三氏病(Charcot-Marie-Tooth disease);化學療法誘導性神經病及神經性疼痛;恰裏畸形(Chiari malformation);舞蹈病;慢性炎症性脫髓鞘性多發性神經病;慢性疼痛;慢性區域性疼痛症候群;科-勒二氏症候群(Coffin Lowry syndrome);昏迷,包含持續性植物人狀態;先天性面癱;皮質基底退化;顱動脈炎;顱縫早閉;克雅氏病(Creutzfeldt-Jakob disease);積累性創傷病症;庫興氏症候群(Cushing's syndrome);巨細胞包涵體病;巨細胞病毒感染;舞蹈眼-舞蹈足症候群;丹-沃二氏症候群(DandyWalker syndrome);道森病(Dawson disease);德摩西埃症候群(De Morsier's syndrome);克隆普克-克隆普克症候群(Dejerine-Klumke palsy);癡呆;皮肌炎;糖尿病神經病變;彌漫性硬化;自主神經機能異常;書寫困難;誦讀困難;張力失常;早期幼兒癲癇性腦病;空蝶鞍症候群;腦炎;腦疝;腦三叉神經血管瘤病;癲癇症;歐勃麻痺(Erb's palsy);特發性震顫;法布裏病(Fabry's disease);法爾症候群(Fahr's syndrome);昏厥;家族性痙攣性癱瘓;發熱性驚厥;菲希爾症候群(Fisher syndrome);弗裏德賴希共濟失調症(Friedreich's ataxia);額顳骨癡呆症及其他「tau病
變」;高歇氏病(Gaucher's disease);格斯特曼症候群(Gerstmann's syndrome);巨細胞動脈炎;巨細胞性包涵體病;球樣細胞腦白質營養不良;格-巴二氏症候群(Guillain-Barre syndrome);HTLV-1相關性脊髓病;哈-斯二氏病(Hallervorden-Spatz disease);頭部損傷;頭痛;半面痙攣;遺傳性痙攣性截癱;遺傳病性多神經炎樣共濟失調;耳部帶狀疱疹;帶狀疱疹;平山症候群(Hirayama syndrome);HIV相關性癡呆及神經病(以及AIDS之神經表現);前腦無裂畸形;亨廷頓病(Huntington's disease)及其他聚麩胺醯胺重複疾病;積水性無腦畸形;腦積水;皮質醇增多症;缺氧;免疫介導性腦脊髓炎;包涵體肌炎;色素失調症;嬰兒植烷酸貯積病;嬰兒雷弗蘇姆病infantile refsum disease);嬰兒痙攣;炎性肌病;顱內囊腫;顱內高壓;朱伯特症候群(Joubert syndrome);科姆斯-塞爾症候群(Keams-Sayre syndrome);肯尼迪氏病(Kennedy disease);金斯布林納症候群(Kinsboume syndrome);克-費二氏症候群(Klippel Feil syndrome);克拉伯病(Krabbe disease);庫格爾貝格-韋蘭德病(Kugelberg-Welander disease);庫魯病(kuru);拉福拉病(Lafora disease);朗-愛二氏肌無力症候群(Lambert-Eaton myasthenic syndrome);蘭達-克萊夫納症候群(Landau-Kleffner syndrome);延髓外側(瓦倫貝克(Wallenberg))症候群;學習失能;利氏病(Leigh's disease);倫諾克斯-加斯托症候群(Lennox-Gustaut syndrome);萊-萘二氏症候群(Lesch-Nyhan syndrome);腦白質營養不良症;路易體癡呆(Lewy body dementia);無腦回;閉鎖症候群;盧-格裏格病(Lou Gehrig's disease)(亦即,運動神經元病或肌萎縮側索硬化);腰椎間盤病;萊姆病(Lyme disease)-神經後遺症;馬-約病(Machado-Joseph disease);腦肥大;巨腦;邁-羅二氏症候群(Melkersson-Rosenthal syndrome);美尼爾症(Menieres disease);髓膜炎;門克斯病(Menkes disease);異染性腦白質營養不
良;小頭畸型;偏頭痛;米勒.費希爾症候群(Miller Fisher syndrome);小中風;線粒體肌病;默比烏斯症候群(Mobius syndrome);單肢肌萎縮;運動神經元病;腦底異常血管網病;黏多糖累積病;多發梗塞性癡呆;多灶性運動神經病;多發性硬化及其他去髓鞘病症;具有位置性低血壓之多系統萎縮;肌營養不良症;重症肌無力;去髓鞘彌漫性硬化;嬰兒肌陣攣性腦病;肌陣攣;肌病;肌強直;嗜眠症;神經纖維瘤病;神經阻滯劑惡性症候群;AIDS之神經表現;狼瘡之神經後遺症;神經性肌強直;神經元臘樣脂褐質症;腦神經元移行異常;尼曼皮克病(Niemann-Pick disease);奧沙利文-麥克勞德病症(O'Sullivan-McLeod syndrome);枕部神經痛;隱性脊柱神經管閉合不全序列徵;大田原症候群(Ohtahara syndrome);橄欖體腦橋小腦萎縮;斜視性眼陣攣;視神經炎;直立性低血壓;過度使用症候群;感覺異常;神經退化性疾病或病症(帕金森氏病(Parkinson's disease)、亨廷頓病、阿爾茨海默氏病、肌萎縮側索硬化(ALS)、癡呆、多發性硬化及與神經元細胞死亡有關之其他疾病及病症);先天性副肌強直症;副腫瘤性疾病;陣發性發作;帕-羅二氏症候群(Parry Romberg syndrome);佩-梅二氏病(Pelizaeus-Merzbacher disease);週期性癱瘓;周邊神經病;疼痛性神經病及神經性疼痛;持續性植物人狀態;全身性發育遲緩;旋光性噴嚏反射;植烷酸貯積病;匹克病(Pick's disease);神經挾捏;垂體瘤;多肌炎;腦穿通畸形;小兒麻痺症後期症候群;帶狀皰疹後神經痛;感染後腦脊髓炎;體位性低血壓;帕-魏二氏症候群(Prader-Willi syndrome);原發性側索硬化症,;朊病毒病;進行性一側面萎縮;進行性多灶性白質腦病;進行性硬化性灰質萎縮;進行性核上麻痺;假腦瘤;拉姆齊-亨特症候群(Ramsay-Hunt syndrome)(I及II型);羅斯默森氏腦炎(Rasmussen's encephalitis);反射性交感神經營養不良症候群;雷夫敘姆病(Refsum
disease);重複性運動病症;重複性壓迫損傷;不寧腿症候群;反轉錄病毒相關性脊髓病;蕾特氏症候群(Rett syndrome);雷依氏症候群(Reye's syndrome);舞蹈病(Saint Vitus dance);山德霍夫氏病(Sandhoff disease);謝耳德病(Schilder's disease);腦裂;透明隔-視神經發育不良;驚嚇嬰兒症候群;帶狀疱疹;夏伊-德雷格症候群(Shy-Drager syndrome);薛格連氏症候群(Sjogren's syndrome);睡眠呼吸暫停;索托斯症候群(Soto's syndrome);痙攣狀態;脊柱裂;脊髓損傷;脊髓腫瘤;脊髓性肌萎縮;僵人症候群(Stiff-Person syndrome);中風;斯特奇-韋伯二氏症候群(Sturge-Weber syndrome);亞急性硬化性全腦炎;皮層下動脈硬化性腦病;西德納姆舞蹈病(Sydenham chorea);暈厥;脊髓空洞症;遲發性運動障礙;泰-薩克斯病(Tay-Sachs disease);顳動脈炎;脊髓牽扯症候群;湯姆森病(Thomsen disease);胸廓出口症候群;三叉神經痛症(Tic Douloureux);託德氏麻痺(Todd's paralysis);多動穢語症候群;短暫性腦缺血發作;傳播性海綿狀腦病;橫貫性脊髓炎;外傷性腦損傷;顫抖;三叉神經痛;熱帶痙攣性輕截癱;結節性硬化症;血管性癡呆(多發梗塞性癡呆);血管炎,包含顳動脈炎;希林二氏病(Von Hippel-Lindau disease);瓦倫伯格氏症候群(Wallenberg's syndrome);韋德尼希-霍夫曼病(Werdnig-Hoffman disease);韋斯特病(West syndrome);頸椎戳傷;威廉斯症候群(Williams syndrome);威爾森氏病(Wildon's disease);及澤韋格症候群(Zellweger syndrome)。
「增殖性疾病或病症」包含但不限於涉及以下細胞之造血腫瘤性病症:源於骨髓樣、淋巴樣或紅血球譜系之造血源的增生性/腫瘤性細胞、或其前體細胞。該等疾病包含但不限於成紅細胞白血病、急性前骨髄性白血病(APML)、慢性髓性白血病(CML)、淋巴樣惡性腫瘤(包含但不限於急性成淋巴細胞性白血病(ALL),其包含B-譜系ALL
及T-譜系ALL)、慢性淋巴細胞白血病(CLL)、幼淋巴細胞白血病(PLL)、多毛細胞白血病(HLL)及沃爾登斯特倫巨球蛋白血症(Waldenstrom's macroglobulinemia)(WM)。惡性淋巴瘤之其他形式包含但不限於非霍奇金氏淋巴瘤及其變體、周邊T細胞淋巴瘤、成人T細胞白血病/淋巴瘤(ATL)、皮膚T細胞淋巴瘤(CTCL)、巨粒淋巴細胞白血病(LGF)、霍奇金氏病及裏德-斯藤伯格病(Reed-Sternberg disease)。
靶:在一實施例中,靶包括PAR4之核酸序列,包含(不限於)與PAR4有關之正股及/或反股非編碼及/或編碼序列。
前列腺細胞凋亡反應-4(PAR4)係最初以發生細胞凋亡之前列腺腫瘤細胞中特異性上調之基因產物形式鑑別的38kDa蛋白質。與PAR4在細胞凋亡中之重要作用一致,發現在細胞凋亡期間PAR4在培養細胞中之誘導具有排他性,且PAR4在N1H-3T3細胞、神經元、前列腺癌及黑素瘤細胞中之異位表現已顯示可使該等細胞對細胞凋亡刺激敏感。此外,下調PAR4對於ras誘導之存活及腫瘤進展至關重要,且藉由反股技術來阻抑PAR4產生可防止若干系統(包含神經退化性病症之不同模型)中之細胞凋亡,此進一步強調了PAR4在細胞凋亡中之重要作用。在羧基末端,PAR4含有亮胺酸拉鏈結構域、及部分重疊之死亡結構域(Par4DD,胺基酸258-332)。此羧基末端部分之缺失會使PAR4之凋亡前功能喪失。另一方面,PAR4亮胺酸拉鏈/死亡結構域之過度表現以顯性陰性方式發揮作用以防止由全長PAR4誘導之細胞凋亡。PAR4亮胺酸拉鏈/死亡結構域可藉由識別以下兩類不同基序來調介PAR4與其他蛋白質之相互作用:Wilms腫瘤抑制蛋白WT1之鋅指及蛋白激酶C之典型同種型、及來自死亡相關蛋白(DAP)樣激酶Dlk之富精胺酸結構域。在該等相互作用中,PAR4與aPKC之結合及其酶活
性之所得抑制尤其具有功能相關性,此乃因已知PKC在細胞存活中發揮重要作用且已顯示其過度表現可使PAR4誘導細胞凋亡之能力喪失。
在一實施例中,使用反股寡核苷酸來預防或治療與PAR4家族成員有關之疾病或病症。可使用自利用反股化合物獲得之幹細胞再生之細胞/組織治療的實例性PAR4介導之疾病及病症包括:與PAR4之異常功能及/或表現有關之疾病或病症、癌症、異常細胞凋亡、增殖性疾病或病症、心血管疾病或病症、炎性疾病或病症、神經性疾病或病症及衰老。
在一實施例中,對有需要之患者實施藉由一或多種反股寡核苷酸來調節PAR4,從而預防或治療與PAR4異常表現、功能、活性(與正常對照相比)有關的任一疾病或病症。
在一實施例中,寡核苷酸對PAR4之多核苷酸具有特異性,其包含(不限於)非編碼區域。PAR4靶包括PAR4之變體;PAR4之突變體,包含NP;PAR4之非編碼序列;等位基因、片段及諸如此類。較佳地,寡核苷酸係反股RNA分子。
根據本發明實施例,靶核酸分子並不僅限於PAR4多核苷酸而是擴展至PAR4之任一同種型、受體、同系物、非編碼區域及諸如此類。
在一實施例中,寡核苷酸靶向PAR4靶之天然反股序列(編碼及非編碼區域之天然反股序列),其包含(不限於)其變體、等位基因、同系物、突變體、衍生物、片段及互補序列。較佳地,寡核苷酸係反股RNA或DNA分子。
在一實施例中,本發明之寡聚化合物亦包含在該化合物中之一或多個核苷酸位置存在不同鹼基的變體。舉例而言,若第一核苷酸係腺嘌呤,則可產生在此位置含有胸苷、鳥苷、胞苷或其他天然或非天
然核苷酸之變體。此可發生於反股化合物之任一位置。然後使用本文所述方法測試該等化合物以測定其抑制靶核酸表現之能力。
在一些實施例中,反股化合物及靶之間之同源性、序列一致性或互補性為約50%至約60%。在一些實施例中,同源性、序列一致性或互補性為約60%至約70%。在一些實施例中,同源性、序列一致性或互補性為約70%至約80%。在一些實施例中,同源性、序列一致性或互補性為約80%至約90%。在一些實施例中,同源性、序列一致性或互補性為約90%、約92%、約94%、約95%、約96%、約97%、約98%、約99%或約100%。
在以下情形時反股化合物係可特異性雜交:化合物與靶核酸之結合可干擾靶核酸之正常功能而導致活性損失,且存在足夠互補性程度以避免反股化合物與非靶核酸序列在期望發生特異性結合之條件下發生非特異性結合。該等條件包含(亦即)活體內分析或治療性治療情形下之生理條件、及在活體外分析情形下實施分析之條件。
在以下情形下反股化合物(不論係DNA、RNA、嵌合化合物、或經取代化合物等)可特異性雜交:該化合物與靶DNA或RNA分子之結合可干擾靶DNA或RNA之正常功能而導致實用性損失,且存在足夠互補性程度以避免反股化合物與非靶序列在期望發生特異性結合之條件下(亦即,在活體內分析或治療性治療情形下之生理條件下,或在活體外分析情形下實施分析之條件下)發生非特異性結合。
在一實施例中,靶向PAR4(包含(不限於)使用(例如)PCR、雜交等鑑別及擴展之反股序列、闡述為SEQ ID NO:2之序列之一或多者及諸如此類)可調節PAR4之表現或功能。在一實施例中,與對照相比上調表現或功能。在一實施例中,與對照相比下調表現或功能。
在一實施例中,寡核苷酸包括闡述為SEQ ID NO:3至9之核酸序列,包含使用(例如)PCR、雜交等鑑別及擴展之反股序列。該等寡核
苷酸可包括一或多個經修飾核苷酸、較短或較長片段、經修飾鍵及諸如此類。經修飾鍵或核苷酸間鍵聯之實例包括硫代磷酸酯、二硫代磷酸酯或諸如此類。在一實施例中,核苷酸包括磷衍生物。可附接至本發明經修飾寡核苷酸中之糖或糖類似物部分之磷衍生物(或經修飾磷酸酯基團)可為單磷酸酯、二磷酸酯、三磷酸酯、磷酸烷基酯、烷磷酸酯、硫代磷酸酯及諸如此類。上述磷酸酯類似物之製備、及其在核苷酸、經修飾核苷酸及寡核苷酸中之納入本身亦已知且無需闡述於本文中。
彼等熟習此項技術者亦在治療應用中利用反股寡核苷酸之特異性及敏感性。採用反股寡核苷酸作為治療部分來治療動物及人類之疾病狀態。反股寡核苷酸已安全且有效地投與人類且當前正實施許多臨床試驗。由此確定,寡核苷酸可為可經設置用於治療細胞、組織及動物(尤其人類)之治療方案中的有用治療方式。
在本發明實施例中,寡聚反股化合物、尤其寡核苷酸會結合至靶核酸分子並調節由靶基因編碼之分子的表現及/或功能。擬干擾之DNA功能包括(例如)複製及轉錄。擬干擾之RNA功能包括所有重要功能,例如,RNA至蛋白質轉譯位點之異位、蛋白質自RNA之轉譯、使RNA產生一或多種mRNA物質之剪接、及RNA可參與或促進之催化活性。可端視期望功能來上調或抑制功能。
反股化合物包含反股寡聚化合物、反股寡核苷酸、外部引導序列(EGS)寡核苷酸、交替剪接、引物、探針、及其他與靶核酸之至少一部分雜交的寡聚化合物。因此,該等化合物可以單鏈、雙鏈、部分單鏈、或環狀寡聚化合物形式引入。
在本發明之上下文中,反股化合物至特定核酸分子之靶向可為多步過程。該過程經常始於鑑別調節功能之靶核酸。舉例而言,此靶核酸可為表現與特定病症或疾病狀態有關之細胞基因(或自該基因轉
錄之mRNA)或來自傳染原之核酸分子。在本發明中,靶核酸編碼PAR4。
靶向過程經常亦包含測定靶核酸內發生反股相互作用從而產生期望效應(例如,調節表現)的至少一個靶區域、區段、或位點。在本發明之上下文內,術語「區域」定義為靶核酸中具有至少一個可鑑別結構、功能、或特性的一部分。靶核酸之區域內具有區段。「區段」定義為靶核酸內區域之較小或子部分。本發明所用之「位點」定義為靶核酸內之位置。
在一實施例中,反股寡核苷酸結合至PAR4之天然反股序列並調節PAR4(SEQ ID NO:1)之表現及/或功能。反股序列之實例包含EQ ID NO:2至9。
在一實施例中,反股寡核苷酸結合至PAR4多核苷酸之一或多個區段並調節PAR4之表現及/或功能。區段包括PAR4正股或反股多核苷酸之至少5個連續核苷酸。
在一實施例中,反股寡核苷酸對PAR4之天然反股序列具有特異性,其中寡核苷酸與PAR4之天然反股序列之結合可調節PAR4的表現及/或功能。
在一實施例中,寡核苷酸化合物包括闡述為SEQ ID NO:3至9之序列、使用(例如)PCR、雜交等鑑別及擴展之反股序列。該等寡核苷酸可包括一或多個經修飾核苷酸、較短或較長片段、經修飾鍵及諸如此類。經修飾鍵或核苷酸間鍵聯之實例包括硫代磷酸酯、二硫代磷酸酯或諸如此類。在一實施例中,核苷酸包括磷衍生物。可附接至本發明經修飾寡核苷酸中之糖或糖類似物部分之磷衍生物(或經修飾磷酸酯基團)可為單磷酸酯、二磷酸酯、三磷酸酯、磷酸烷基酯、烷磷酸酯、硫代磷酸酯及諸如此類。上述磷酸酯類似物之製備、及其在核苷酸、經修飾核苷酸及寡核苷酸中之納入本身亦已知且無需闡述於本文
中。
如業內已知,因轉譯起動密碼子通常係5'-AUG(在轉錄mRNA分子中;在相應DNA分子中係5'-ATG),轉譯起動密碼子亦稱為「AUG密碼子」、「起始密碼子」或「AUG起始密碼子」。少數基因具有轉譯起動密碼子,其具有RNA序列5'-GUG、5'-UUG或5'-CUG;且已顯示5'-AUA、5'-ACG及5'-CUG可在活體內發揮作用。因此,即使起動胺基酸在每一情形中通常係甲硫胺酸(在真核生物中)或甲醯甲硫胺酸(在原核生物中),術語「轉譯起動密碼子」及「起始密碼子」亦可涵蓋多種密碼子序列。真核生物及原核生物基因可具有兩個或更多個替代性起始密碼子,其中之任一者可優先用於在特定細胞類型或組織中或在特定條件組下之轉譯起動。在本發明之上下文中,「起始密碼子」及「轉譯起動密碼子」係指用於在活體內起動自編碼PAR4之基因轉錄之mRNA之轉譯的一或多個密碼子,不管該等密碼子之序列如何。基因之轉譯終止密碼子(或「停止密碼子」)可具有三種序列(亦即,5'-UAA、5'-UAG及5'-UGA,相應DNA序列分別係5'-TAA、5'-TAG及5'-TGA)中之一者。
術語「起始密碼子區域」及「轉譯起動密碼子區域」係指此一mRNA或基因中在來自轉譯起動密碼子之任一方向(亦即,5'或3')涵蓋約25至約50個鄰近核苷酸的一部分。同樣,術語「停止密碼子區域」及「轉譯終止密碼子區域」係指此一mRNA或基因中在來自轉譯終止密碼子之任一方向(亦即,5'或3')涵蓋約25至約50個鄰近核苷酸的一部分。因此,「起始密碼子區域」(或「轉譯起動密碼子區域」)及「停止密碼子區域」(或「轉譯終止密碼子區域」)係本發明反股化合物可有效靶向之所有區域。
業內已知之開放讀碼框(ORF)或「編碼區域」係指轉譯起動密碼子及轉譯終止密碼子之間之區域,其亦係可有效靶向之區域。在本發
明之上下文內,靶向區域係涵蓋基因之開放讀碼框(ORF)之轉譯起動或終止密碼子的基因內區域。
另一靶區域包含業內已知之5'非轉譯區域(5'UTR),其係指在來自轉譯起動密碼子之5'方向上之mRNA部分,且由此包含mRNA之5'加帽位點及轉譯起動密碼子間之核苷酸(或基因上之相應核苷酸)。另一靶區域包含業內已知之3'非轉譯區域(3'UTR),其係指在來自轉譯終止密碼子之3'方向上之mRNA部分,且由此包含mRNA之轉譯終止密碼子及3'端間之核苷酸(或基因上之相應核苷酸)。mRNA之5'加帽位點包括經由5'-5'三磷酸酯鍵聯接合至mRNA之5'-最殘基之N7-甲基化鳥苷殘基。mRNA之5'加帽區域視為包含5'加帽結構本身以及與加帽位點相鄰之前50個核苷酸。本發明之另一靶區域係5'加帽區域。
儘管一些真核生物mRNA轉錄本可直接轉譯,但許多真核生物mRNA轉錄本含有一或多個在轉譯之前自轉錄本切割且稱為「內含子」的區域。剩餘(且由此轉譯)區域稱為「外顯子」且一起剪接以形成連續mRNA序列。在一實施例中,靶向剪接位點(亦即,內含子-外顯子結點或外顯子-內含子結點)尤其可用於異常剪接與疾病有關、或特定剪接產物之過度產生與疾病有關之情形中。因重排或缺失產生之異常融合結點係靶位點之另一實施例。經由自不同基因源剪接兩個(或更多)mRNA之過程產生之mRNA轉錄本稱為「融合轉錄本」。可使用靶向(例如)DNA或mRNA前體之反股化合物來有效靶向內含子。
在一實施例中,反股寡核苷酸結合至靶多核苷酸之編碼及/或非編碼區域並調節靶分子之表現及/或功能。
在一實施例中,反股寡核苷酸結合至天然反股多核苷酸並調節靶分子之表現及/或功能。
在一實施例中,反股寡核苷酸結合至正股多核苷酸並調節靶分子之表現及/或功能。
替代性RNA轉錄本可自DNA之相同基因組區域產生。該等替代性轉錄本通稱為「變體」。更特定而言,「mRNA前體變體」係自相同基因組DNA產生之轉錄本,其與自相同基因組DNA產生之其他轉錄本在起始或停止位置方面有所不同且含有內含子及外顯子序列。
在剪接期間切割一或多個外顯子或內含子區域、或其部分時,mRNA前體變體會產生較小「mRNA變體」。因此,mRNA變體係經處理之mRNA前體變體且每一唯一mRNA前體變體必須始終藉由剪接而產生唯一mRNA變體。該等mRNA變體亦稱為「交替剪接變體」。若mRNA前體變體未發生剪接,則mRNA前體變體與mRNA變體相同。
變體可經由使用起始或停止轉錄之交替信號來產生。mRNA前體及mRNA可具有一個以上之起始密碼子或停止密碼子。源自使用替代性起始密碼子之mRNA前體或mRNA的變體稱為mRNA前體或mRNA之「替代性起始變體」。彼等使用替代性停止密碼子之轉錄本稱為mRNA前體或mRNA之「替代性停止變體」。替代性停止變體之一種具體類型係「polyA變體」,其中所產生之多個轉錄本源自轉錄機對於「polyA停止信號」中之一者之替代性選擇,由此產生在唯一polyA位點終止之轉錄本。在本發明之上下文內,本文所述變體之類型亦係靶核酸之實施例。
靶核酸上與反股化合物雜交之位置至少定義為靶區域中由活性反股化合物靶向之長5個核苷酸的部分。
儘管本文中闡述了某些實例性靶區段之特異性序列,但熟習此項技術者應認識到,該等序列用於闡釋及闡述本發明範圍內之特定實施例。熟習此項技術者根據本揭示內容可容易地鑑別其他靶區段。
人們認為長度為5-100個核苷酸且包括一段至少五(5)個選自較佳闡釋性靶區段之連續核苷酸之靶區段亦適於靶向。
靶區段可包含DNA或RNA序列,其包括至少5個來自較佳闡釋性
靶區段中之一者之5'-末端之連續核苷酸(剩餘核苷酸係同一DNA或RNA中之連續的一段,其緊接靶區段之5'-末端上游開始並持續至該DNA或RNA含有約5至約100個核苷酸為止)。同樣,較佳靶區段表示為DNA或RNA序列,其包括至少5個來自較佳闡釋性靶區段中之一者之3'-末端之連續核苷酸(剩餘核苷酸係同一DNA或RNA中之連續的一段,其緊接靶區段之3'-末端下游開始並持續至該DNA或RNA含有約5至約100個核苷酸為止)。瞭解本文所示靶區段之熟習此項技術者無需過多實驗即能鑑別其他較佳靶區段。
鑑別一或多個靶區域、區段或位點後,即可選擇與靶充分互補(亦即雜交足夠充分且具有足夠特異性)之反股化合物以得到期望效應。
在本發明實施例中,寡核苷酸結合至特定靶之反股鏈。寡核苷酸之長度為至少5個核苷酸且可經合成以使每一寡核苷酸皆靶向重疊序列,從而寡核苷酸經合成以覆蓋靶多核苷酸之整個長度。靶亦包含編碼以及非編碼區域。
在一實施例中,反股寡核苷酸較佳靶向特異性核酸。反股化合物至特定核酸之靶向係多步過程。該過程經常始於鑑別調節功能之核酸序列。此可(例如)係表現與特定病症或疾病狀態有關之細胞基因(或自基因轉錄之mRNA)、或非編碼多核苷酸(例如,非編碼RNA(ncRNA))。
RNA可分類為(1)信使RNA(mRNA),其轉譯成蛋白質;及(2)非蛋白編碼性RNA(ncRNA)。ncRNA包括微小RNA、反股轉錄本及含有高密度停止密碼子且缺乏任一廣泛性(extensive)「開放讀碼框」的其他轉錄單元(TU)。許多ncRNA似乎始於編碼蛋白質之基因座之3'非轉譯區域(3'UTR)中之起動位點。ncRNA通常較罕見且FANTOM聯盟已測序之ncRNA中至少一半似乎未經聚腺苷酸化。大部分研究者出於明
顯原因而著重關注經處理並輸出至細胞質中之聚腺苷酸化mRNA。最近,顯示非聚腺苷酸化核RNA之組可能極大,且許多該等轉錄本源自所謂的基因間區域。ncRNA可調控基因表現之機制係與靶轉錄本之鹼基配對。藉由鹼基配對發揮作用之RNA可分組為:(1)順式編碼之RNA,其在其發揮作用之相同遺傳位置、但在RNA之相對鏈處編碼且由此顯示與其靶之完全互補性;及(2)反式編碼之RNA,其在與其發揮作用之RNA不同的染色體位置處編碼且通常並不顯示與其靶之完全鹼基配對潛力。
不期望受限於理論,本文所述反股寡核苷酸對反股多核苷酸之干擾可改變相應正股信使RNA之表現。然而,此調控可不協調(反股敲減(knockdown)造成信使RNA增加)或協調(反股敲減造成伴隨信使RNA減少)。在該等情形下,反股寡核苷酸可靶向反股轉錄本之重疊或非重疊部分以產生敲減或隔絕(sequestration)。可以相同方式靶向編碼以及非編碼反股轉錄本,且任一種類皆能以協調或不協調方式調控相應正股轉錄本。在鑑別針對靶使用之新寡核苷酸時採用的策略可基於藉由反股寡核苷酸來敲減反股RNA轉錄本或調節期望靶的任一其他方式。
策略1:在不協調調控之情形下,敲減反股轉錄本會增加習用(正股)基因之表現。若習用基因編碼已知或假定藥物靶,則可設想敲減其反股對等部分來模擬受體激動劑或酶刺激物之作用。
策略2:在協調調控之情形下,可同時敲減反股及正股轉錄本且由此達成習用(正股)基因表現之協同降低。舉例而言,若使用反股寡核苷酸來達成敲減,則可使用此策略來應用一種靶向正股轉錄本之反股寡核苷酸及靶向相應反股轉錄本之另一反股寡核苷酸、或同時靶向重疊正股及反股轉錄本之單一能量對稱性反股寡核苷酸。
根據本發明,反股化合物包含反股寡核苷酸、核酶、外部引導
序列(EGS)寡核苷酸、siRNA化合物、單-或雙鏈RNA干擾(RNAi)化合物(例如siRNA化合物)、及與靶核酸之至少一部分雜交並調節其功能之其他寡聚化合物。因此,其可為DNA、RNA、類DNA、類RNA、或其混合物,或可為該等物質中一或多者之模擬物。該等化合物可為單鏈、雙鏈、環狀或髮夾寡聚化合物,且可含有諸如內部或末端膨脹、失配或環路等結構要素。反股化合物通常製成直鏈形式,但可經接合或以其他方式製成環狀及/或具支鏈形式。反股化合物可包含諸如以下構成物:經雜交以形成完全或部分雙鏈化合物之兩條鏈,或具有足夠自互補性以進行雜交並形成完全或部分雙鏈化合物之單鏈。兩條鏈可在內部連接以產生游離3'或5'末端或可連接形成連續髮夾結構或環路。髮夾結構可在5'或3'末端含有懸垂部分以延長單鏈特徵。雙鏈化合物視需要可在末端包含懸垂部分。其他修飾可包含附接至一個末端、所選核苷酸位置、糖位置或附接至一個核苷間鍵聯之偶聯基團。另一選擇為,兩條鏈可經由非核酸部分或連接體基團進行連接。在自僅一條鏈形成時,dsRNA可呈自互補髮夾型分子形式,其自身對折以形成雙鏈體。因此,dsRNA可為完全或部分雙鏈。可藉由在轉基因細胞系中穩定表現dsRNA髮夾來特異性調節基因表現,然而,在一些實施例中,基因表現或功能經上調。在自兩條鏈、或呈自互補髮夾型分子形式(自身對折以形成雙鏈體)之單鏈形成時,兩條鏈(或單鏈中形成雙鏈體之區域)係以Watson-Crick方式鹼基配對之互補RNA鏈。
引入系統中之後,本發明化合物可引發一或多種酶或結構蛋白質之作用以實現靶核酸之裂解或其他修飾或可經由基於佔據之機制進行作用。一般而言,核酸(包含寡核苷酸)可闡述為「類DNA」(亦即,通常具有一或多個2'-去氧糖及(通常)T而非U鹼基)或「類RNA」(亦即,通常具有一或多個2'-羥基或2'-修飾糖及(通常)U而非T鹼基)。核酸螺旋可採用一種以上之結構類型,最通常係A型及B型。據信,
一般而言,具有B型樣結構之寡核苷酸係「類DNA」且彼等具有A型樣結構者係「類RNA」。在一些(嵌合)實施例中,反股化合物可含有A-及B型區域。
在一實施例中,期望寡核苷酸或反股化合物包括以下中之至少一者:反股RNA、反股DNA、嵌合反股寡核苷酸、包括經修飾鍵聯反股寡核苷酸、干擾RNA(RNAi)、短干擾RNA(siRNA);微小干擾RNA(miRNA);小時序RNA(stRNA);或短髮夾RNA(shRNA);小RNA誘導之基因活化(RNAa);小活化RNA(saRNA)、或其組合。
dsRNA亦可活化基因表現,此機制稱為「小RNA誘導之基因活化」或RNAa。靶向基因啟動子之dsRNA可誘導相關基因之有效轉錄活化。在使用合成dsRNA(稱為「小活化RNA」(saRNA))之人類細胞中顯示RNAa。當前尚未瞭解,在其他有機體中RNAa是否保守。
已發現,小雙鏈RNA(dsRNA)(例如小干擾RNA(siRNA)及微小RNA(miRNA))係稱為RNA干擾(RNAi)之進化保守機制的觸發物。RNAi通常經由重塑染色質以由此阻抑轉錄來引起基因沉默,從而降解互補mRNA、或阻斷蛋白質轉譯。然而,在詳細闡述於下文實例部分之情形下,顯示寡核苷酸可增加PAR4多核苷酸及其編碼產物之表現及/或功能。dsRNA亦可用作小活化RNA(saRNA)。不期望受限於理論,藉由靶向基因啟動子中之序列,saRNA可誘導靶基因表現,此現象稱為dsRNA誘導之轉錄活化(RNAa)。
在另一實施例中,本文所鑑別之「較佳靶區段」可用於篩選調節PAR4多核苷酸之表現之額外化合物。「調節劑」係彼等如下化合物:可降低或增加編碼PAR4之核酸分子之表現,且至少包括與較佳靶區段互補之5-核苷酸部分。篩選方法包括以下步驟:使編碼PAR4之正股或天然反股多核苷酸之核酸分子的較佳靶區段與一或多種候選調節劑接觸,且選擇一或多種可降低或增加編碼PAR4多核苷酸之核
酸分子(例如SEQ ID NO:3至9)之表現的候選調節劑。若顯示一或多種候選調節劑能夠調節(例如降低或增加)編碼PAR4多核苷酸之核酸分子的表現,則該調節劑可用於PAR4多核苷酸功能之其他調查性研究,或用作本發明之研究、診斷、或治療藥劑。
靶向天然反股序列較佳地可調節靶基因之功能。例如,PAR4基因(例如,登錄號為NM_002583)。在一實施例中,靶係PAR4基因之反股多核苷酸。在一實施例中,反股寡核苷酸靶向PAR4多核苷酸(例如,登錄號為NM_002583)之正股及/或天然反股序列、其變體、等位基因、同種型、同系物、突變體、衍生物、片段及互補序列。較佳地,寡核苷酸係反股分子且靶包含反股及/或正股PAR4多核苷酸之編碼及非編碼區域。
本發明之較佳靶區段亦可與本發明之其相應互補反股化合物組合以形成穩定雙鏈(雙鏈體)寡核苷酸。
業內已顯示,該等雙鏈寡核苷酸部分可調節靶表現並經由反股機制調控轉譯以及RNA處理。另外,雙鏈部分可經受化學修飾。舉例而言,已顯示該等雙鏈部分可藉由雙鏈體之反股鏈與靶之典型雜交來抑制靶,由此觸發靶之酶降解。
在一實施例中,反股寡核苷酸靶向PAR4多核苷酸(例如,登錄號為NM_002583)、其變體、等位基因、同種型、同系物、突變體、衍生物、片段及互補序列。較佳地,寡核苷酸係反股分子。
根據本發明實施例,靶核酸分子並不僅限於PAR4而是擴展至PAR4分子之任一同種型、受體、同系物及諸如此類。
在一實施例中,寡核苷酸靶向PAR4多核苷酸之天然反股序列(例如,闡述為SEQ ID NO:2之多核苷酸)、及其任一變體、等位基因、同系物、突變體、衍生物、片段及互補序列。將反股寡核苷酸之實例闡述為SEQ ID NO:3至9。
在一實施例中,寡核苷酸與PAR4反股分子之核酸序列(包含(不限於)與PAR4多核苷酸有關之非編碼正股及/或反股序列)互補或結合並調節PAR4分子之表現及/或功能。
在一實施例中,寡核苷酸與PAR4天然反股分子之核酸序列(闡述為SEQ ID NO:2)互補或結合並調節PAR4分子之表現及/或功能。
在一實施例中,寡核苷酸包括SEQ ID NO:3至9中至少5個連續核苷酸之序列並調節PAR4分子之表現及/或功能。
多核苷酸靶包括PAR4(包含其家族成員)、PAR4之變體;PAR4之突變體,包含SNP;PAR4之非編碼序列;PAR4之等位基因;物種變體、片段及諸如此類。較佳地,寡核苷酸係反股分子。
在一實施例中,靶向PAR4多核苷酸之寡核苷酸包括:反股RNA、干擾RNA(RNAi)、短干擾RNA(siRNA);微小干擾RNA(miRNA);小時序RNA(stRNA);或短髮夾RNA(shRNA);小RNA誘導之基因活化(RNAa);或小活化RNA(saRNA)。
在一實施例中,靶向PAR4多核苷酸(例如SEQ ID NO:2至9)可調節該等靶之表現或功能。在一實施例中,與對照相比上調表現或功能。在一實施例中,與對照相比下調表現或功能。
在一實施例中,反股化合物包括闡述為SEQ ID NO:3至9之序列。該等寡核苷酸可包括一或多個經修飾核苷酸、較短或較長片段、經修飾鍵及諸如此類。
在一實施例中,SEQ ID NO:3至9包括一或多個LNA核苷酸。表1顯示用於本發明方法中之實例性反股寡核苷酸。
可以業內已知之若干方式來調節期望靶核酸。舉例而言,使用反股寡核苷酸、siRNA等。酶性核酸分子(例如,核酶)係能夠催化一或多種不同反應之核酸分子,包含能夠以核苷酸鹼基序列特異性方式重複裂解其他單獨核酸分子。該酶性核酸分子可用於(例如)靶向實質上任一RNA轉錄本。
因具有序列特異性,故反式裂解之酶性核酸分子可顯示用作人類疾病之治療劑的前景。可設計酶性核酸分子來裂解細胞RNA背景內之特異性RNA靶。此一裂解事件使得mRNA失去功能性並去除來自該RNA之蛋白質表現。以此方式可選擇性抑制與疾病狀態有關之蛋白質的合成。
一般而言,具有RNA裂解活性之酶性核酸藉由首先結合至靶RNA來發揮作用。該結合經由酶性核酸之靶結合部分來進行,該靶結合部分緊鄰分子中用於裂解靶RNA之酶性部分。因此,酶性核酸首先識別靶RNA且然後經由互補鹼基配對與靶RNA結合,且在結合至確切位點後以酶促方式發揮作用以切割靶RNA。此一靶RNA之裂解策略將破壞其引導合成所編碼蛋白之能力。酶性核酸已結合且裂解其RNA靶之後,其自該RNA釋放以尋找另一靶且可重複結合及裂解新靶。
已使用諸如活體外選擇(演變)策略(Orgel,(1979)Proc.R.Soc.London,B 205,435)等若干方式來產生能夠催化各種反應(例如磷酸二
酯鍵聯及醯胺鍵聯之裂解及連接)的新核酸觸媒。
對於具有最適催化活性之核酶之研發將顯著有助於採用RNA裂解性核酶來調控基因表現的任一策略。舉例而言,錘頭狀核酶在飽和(10mM)濃度之Mg2+輔因子存在下以約1min-1之催化速率(kcat)發揮作用。已顯示人工「RNA連接酶」核酶可以約100min-1之速率催化相應自修飾反應。此外,已知某些經修飾錘頭狀核酶具有由DNA構成之受質結合臂,其可以接近100min-1之多倍周轉速率催化RNA裂解。最後,使用某些核苷酸類似物代替錘頭狀核酶催化核心內之特定殘基可產生經修飾核酶,其催化速率顯示提高多達10倍。該等發現表明,核酶可以顯著大於大部分天然自裂解核酶在活體外所顯示之催化速率的催化速率來促進化學轉化。然後可優化某些自裂解核酶之結構以得到最大催化活性,或可製備顯示顯著較快之RNA磷酸二酯裂解速率之全新RNA基序。
符合「錘頭」模型之RNA觸媒催化之RNA受質的分子間裂解首次顯示於1987年(Uhlenbeck,O.C.(1987)Nature,328:596-600)。回收RNA觸媒並使其與多個RNA分子進行反應,從而表明其確實具有催化性。
基於「錘頭」基序設計之催化RNA已用於裂解特異性靶序列,其係藉由在催化RNA中作出適當鹼基改變以維持與靶序列之必需鹼基配對來達成。此使得可使用催化RNA來裂解特異性靶序列,且表明根據「錘頭」模型設計之催化RNA可在活體內裂解特異性受質RNA。
RNA干擾(RNAi)已成為調節哺乳動物及哺乳動物細胞中之基因表現之有效工具。此方式需要使用表現質粒或病毒及用於處理成siRNA之小髮夾RNA的編碼序列以RNA自身或DNA形式來遞送小干擾RNA(siRNA)。此系統使得能夠將siRNA前體有效輸送至其具有活性之細胞質中且容許使用用於基因表現之經調控及組織特異性啟動子。
在一實施例中,寡核苷酸或反股化合物包括核糖核酸(RNA)及/或去氧核糖核酸(DNA)之寡聚物或聚合物、或其模擬物、嵌合體、類似物或同系物。此術語包含由天然存在之核苷酸、糖及共價核苷間(主鏈)鍵聯組成之寡核苷酸;以及具有非天然存在部分且以相似方式發揮作用之寡核苷酸。該等經修飾或經取代寡核苷酸經常優於天然形式,此乃因諸如增強之細胞攝取、對於靶核酸之增強之親和力及在核酸酶存在下之增加之穩定性等期望性質。
根據本發明,寡核苷酸或「反股化合物」包含反股寡核苷酸(例如RNA、DNA、其模擬物、嵌合體、類似物或同系物)、核酶、外部引導序列(EGS)寡核苷酸、siRNA化合物、單鏈或雙鏈RNA干擾(RNAi)化合物(例如siRNA化合物)、saRNA、aRNA、及其他與靶核酸之至少一個部分雜交並調節其功能之寡聚化合物。因此,其可為DNA、RNA、類DNA、類RNA、或其混合物,或可為該等物質中一或多者之模擬物。該等化合物可為單鏈、雙鏈、環狀或髮夾寡聚化合物,且可含有諸如內部或末端膨脹、失配或環路等結構要素。反股化合物通常製成直鏈形式,但可經接合或以其他方式製成環狀及/或具支鏈形式。反股化合物可包含諸如以下構成物:經雜交以形成完全或部分雙鏈化合物之兩條鏈,或具有足夠自互補性以進行雜交並形成完全或部分雙鏈化合物之單鏈。兩條鏈可在內部連接以產生游離3'或5'末端或可連接形成連續髮夾結構或環路。髮夾結構可在5'或3'末端含有懸垂部分以延長單鏈特徵。雙鏈化合物視需要可在末端包含懸垂部分。其他修飾可包含附接至一個末端、所選核苷酸位置、糖位置或附接至一個核苷間鍵聯之偶聯基團。另一選擇為,兩條鏈可經由非核酸部分或連接體基團進行連接。在自僅一條鏈形成時,dsRNA可呈自互補髮夾型分子形式,其自身對折以形成雙鏈體。因此,dsRNA可為完全或部分雙鏈。可藉由穩定表現轉基因細胞系中之dsRNA髮夾來特異
性調節基因表現。在自兩條鏈、或呈自互補髮夾型分子形式(自身對折以形成雙鏈體)之單鏈形成時,兩條鏈(或單鏈中形成雙鏈體之區域)係以Watson-Crick方式鹼基配對之互補RNA鏈。
引入系統中之後,本發明化合物可引發一或多種酶或結構蛋白質之作用以實現靶核酸之裂解或其他修飾或可經由基於佔據之機制進行作用。一般而言,核酸(包含寡核苷酸)可闡述為「類DNA」(亦即,通常具有一或多個2'-去氧糖及(通常)T而非U鹼基)或「類RNA」(亦即,通常具有一或多個2'-羥基或2'-修飾糖及(通常)U而非T鹼基)。核酸螺旋可採用一種以上之結構類型,最通常係A型及B型。據信,一般而言,具有B型樣結構之寡核苷酸係「類DNA」且彼等具有A型樣結構者係「類RNA」。在一些(嵌合)實施例中,反股化合物可含有A-及B型區域。
本發明之反股化合物可包括長度為約5至約80個核苷酸(亦即,約5至約80個連接核苷)的反股部分。此係指反股化合物之反股鏈或部分之長度。換言之,本發明之單鏈反股化合物包括5至約80個核苷酸,且本發明之雙鏈反股化合物(例如,dsRNA)包括長度為5至約80個核苷酸之正股及反股鏈或部分。熟習此項技術者應瞭解,此涵蓋長度為5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59、60、61、62、63、64、65、66、67、68、69、70、71、72、73、74、75、76、77、78、79、或80個核苷酸、或其任一範圍之反股部分。
在一實施例中,本發明之反股化合物具有長度為10至50個核苷酸之反股部分。熟習此項技術者應瞭解,此展現反股部分長度為10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、
26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、或50個核苷酸、或其任一範圍之寡核苷酸。在一些實施例中,寡核苷酸之長度為15個核苷酸。
在一實施例中,本發明之反股或寡核苷酸化合物具有長度為12或13至30個核苷酸的反股部分。熟習此項技術者應瞭解,此展現反股部分長度為12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29或30個核苷酸、或其任一範圍之反股化合物。
在一實施例中,本發明之寡聚化合物亦包含在該化合物中之一或多個核苷酸位置存在不同鹼基的變體。舉例而言,若第一核苷酸係腺嘌呤,則可產生在此位置含有胸苷、鳥苷或胞苷之變體。此可發生於反股或dsRNA化合物之任一位置。然後使用本文所述方法測試該等化合物以測定其抑制靶核酸表現之能力。
在一些實施例中,反股化合物及靶之間之同源性、序列一致性或互補性為約40%至約60%。在一些實施例中,同源性、序列一致性或互補性為約60%至約70%。在一些實施例中,同源性、序列一致性或互補性為約70%至約80%。在一些實施例中,同源性、序列一致性或互補性為約80%至約90%。在一些實施例中,同源性、序列一致性或互補性為約90%、約92%、約94%、約95%、約96%、約97%、約98%、約99%或約100%。
在一實施例中,反股寡核苷酸(例如,SEQ ID NO:3至9中所述之核酸分子)包括一或多個取代或修飾。在一實施例中,核苷酸經鎖核酸(LNA)取代。
在一實施例中,寡核苷酸靶向與PAR4有關之編碼及/或非編碼序列及闡述為SEQ ID NO:1及2之序列之正股及/或反股核酸分子的一或多個區域。寡核苷酸亦靶向SEQ ID NO:1及2之重疊區域。
本發明之某些較佳寡核苷酸係嵌合寡核苷酸。本發明上下文中之「嵌合寡核苷酸」或「嵌合體」係含有兩個或更多個化學上不同之區域之寡核苷酸,每個區域皆由至少一個核苷酸構成。該等寡核苷酸通常含有至少一個經修飾核苷酸區域,該區域賦予一或多種有益性質(例如增加核酸酶抗性,增加細胞攝取,增加與靶之結合親和力);及係能夠裂解RNA:DNA或RNA:RNA雜合體之酶受質的區域。舉例而言,RNase H係可裂解RNA:DNA雙鏈體之RNA鏈之細胞內切核酸酶。因此,活化RNase H可裂解RNA靶,由此大大增強基因表現之反股調節的效率。因此,同與相同靶區域雜交之硫代磷酸酯去氧寡核苷酸相比,在使用嵌合寡核苷酸時利用較短寡核苷酸通常可獲得可比性結果。通常可藉由凝膠電泳及(若需要)業內已知之相關核酸雜交技術來檢測RNA靶之裂解。在一實施例中,嵌合寡核苷酸包括至少一個經修飾以增加靶結合親和力之區域、及(經常)用作RNAse H受質之區域。通常藉由量測寡核苷酸/靶配對之Tm來測定寡核苷酸與其靶(在此情形下係編碼ras之核酸)之親和力,Tm係寡核苷酸與靶離解之溫度;使用分光光度法來檢測離解。Tm愈高,則寡核苷酸與靶之親和力愈大。
本發明之嵌合反股化合物可以兩個或更多個如上所述之寡核苷酸、經修飾寡核苷酸、寡核苷及/或寡核苷酸模擬物之複合結構形式形成。因此,化合物在業內亦稱為雜合體或結合體。教示該等雜合體結構之製備的代表性美國專利包括但不限於美國專利第5,013,830號、第5,149,797號、第5,220,007號、第5,256,775號、第5,366,878號、第5,403,711號、第5,491,133號、第5,565,350號、第5,623,065號、第5,652,355號、第5,652,356號、及第5,700,922號,每一者皆以引用方式併入本文中。
在一實施例中,寡核苷酸之經修飾區域包括至少一個在糖之2'位處修飾的核苷酸,最佳係經2'-O烷基、2'-O-烷基-O-烷基或2'-氟修飾
之核苷酸。在另一實施例中,RNA修飾包含對於嘧啶之核糖、無鹼基殘基或RNA中3'端之反向鹼基之2'-氟、2'-胺基及2'O-甲基修飾。通常將該等修飾納入寡核苷酸中且已顯示該等寡核苷酸相對於2'-去氧寡核苷酸對於給定靶具有較高Tm(亦即,較高靶結合親和力)。該增加之親和力效應大大增強了RNAi寡核苷酸對基因表現之抑制。RNAseH係裂解RNA:DNA雙鏈體中RNA鏈之細胞內切核酸酶;因此,活化此酶可裂解RNA靶,且由此可大大增強RNAi抑制之效率。對RNA靶之裂解通常可藉由凝膠電泳來顯示。在一實施例中,亦對嵌合寡核苷酸進行修飾以增強核酸酶抗性。細胞含有多種可降解核酸之外切核酸酶及內切核酸酶。已顯示多種核苷酸及核苷修飾可使納入該等修飾之寡核苷酸對核酸酶消化之抗性強於天然寡去氧核苷酸。核酸酶抗性通常藉由將寡核苷酸與細胞提取物或分離核酸酶溶液一起培育並在一段時間後經常藉由凝膠電泳量測剩餘完整寡核苷酸之含量來進行量測。已經修飾以增強其核酸酶抗性之寡核苷酸保持完整之時間長於未經修飾之寡核苷酸。已證實多種寡核苷酸修飾可增強或賦予核酸酶抗性。當前,含有至少一個硫代磷酸酯修飾之寡核苷酸更佳。在一些情形下,增強靶結合親和力之寡核苷酸經修飾亦能獨立地增強核酸酶抗性。
擬用於本發明之一些較佳寡核苷酸的具體實例包含彼等包括經修飾主鏈者,該等經修飾主鏈係(例如)硫代磷酸酯、磷酸三酯、膦酸甲酯、短鏈烷基或環烷基糖間鍵聯或短鏈雜原子或雜環糖間鍵聯。最佳者係具有硫代磷酸酯主鏈之寡核苷酸及彼等具有雜原子主鏈者,該等雜原子主鏈尤其係CH2--NH--O--CH2、CH,--N(CH3)--O--CH2[稱為亞甲基(甲基亞胺基)或MMI主鏈]、CH2--O--N(CH3)--CH2、CH2-N(CH3)--N(CH3)--CH2及O--N(CH3)--CH2--CH2主鏈,其中天然磷酸二酯主鏈表示為O--P--O--CH)。由De Mesmaeker等人(1995)Acc.Chem.Res.28:366-374所揭示之醯胺主鏈亦較佳。亦較佳者係具有嗎
啉基主鏈結構之寡核苷酸(Summerton及Weller,美國專利第5,034,506號)。在另一實施例中(例如肽核酸(PNA)主鏈),寡核苷酸之磷酸二酯主鏈由聚醯胺主鏈代替,核苷酸直接或間接結合至聚醯胺主鏈之氮雜氮原子。寡核苷酸亦可包括一或多個經取代糖部分。較佳寡核苷酸在2'位包括下列基團中之一者:OH、SH、SCH3、F、OCN、OCH3OCH3、OCH3O(CH2)n CH3、O(CH2)nNH2或O(CH2)nCH3(n為1至約10);C1-C10低碳烷基、烷氧基、經取代低碳烷基、烷芳基或芳烷基;Cl;Br;CN;CF3;OCF3;O--、S--、或N-烷基;O--、S--、或N烯基;SOCH3;SO2 CH3;ONO2;NO2;N3;NH2;雜環烷基;雜環烷芳基;胺基烷基胺基;聚烷基胺基;經取代甲矽烷基;RNA裂解基團;報導子基團;遷入劑;用於改良寡核苷酸之藥物代謝動力學性質之基團;或用於改良寡核苷酸之藥效動力學性質之基團及其他具有相似性質之取代基。較佳修飾包含2'-甲氧基乙氧基[2'-O-CH2 CH2 OCH3,亦稱為2'-O-(2-甲氧基乙基)]。其他較佳修飾包含2'-甲氧基(2'-O--CH3)、2'-丙氧基(2'-OCH2CH2CH3)及2'-氟(2'-F)。亦可在寡核苷酸上之其他位置進行類似修飾,尤其係3'末端核苷酸上糖之3'位及5'末端核苷酸之5'位。寡核苷酸亦可具有糖模擬物,例如使用環丁基來代替戊呋喃醯基。
寡核苷酸亦可另外或作為另一選擇包含核鹼基(業內通常簡寫為「鹼基」)修飾或取代。本文所用之「未經修飾」或「天然」核苷酸包含腺嘌呤(A)、鳥嘌呤(G)、胸腺嘧啶(T)、胞嘧啶(C)及尿嘧啶(U)。經修飾核苷酸包含僅偶爾或短暫在天然核酸中發現之核苷酸,例如次黃嘌呤、6-甲基腺嘌呤、5-Me嘧啶、尤其5-甲基胞嘧啶(亦稱為5-甲基-2'去氧胞嘧啶且業內通常稱為5-Me-C)、5-羥甲基胞嘧啶(HMC)、糖基HMC及龍膽二糖基HMC;以及合成核苷酸,例如,2-胺基腺嘌呤、2-(甲基胺基)腺嘌呤、2-(咪唑基烷基)腺嘌呤、2-(烷基烷基胺基)
腺嘌呤或其他雜取代烷基腺嘌呤、2-硫尿嘧啶、2-硫胸腺嘧啶、5-溴尿嘧啶、5-羥甲基尿嘧啶、8-氮雜鳥嘌呤、7-去氮鳥嘌呤、N6(6-胺基己基)腺嘌呤及2,6-二胺基嘌呤。可包含業內已知之「常用」鹼基(例如肌苷)。已顯示5-Me-C取代可將核酸雙鏈體穩定性增加0.6-1.2℃且係當前之較佳鹼基取代。
對本發明寡核苷酸之另一修飾涉及使一或多種可增強寡核苷酸之活性或細胞攝取之部分或偶聯物以化學方式連接至寡核苷酸。該等部分包含但不限於脂質部分(例如膽固醇部分)、膽固醇基部分、脂肪族鏈(例如,十二烷二醇或十一烷基殘基)、聚胺或聚乙二醇鏈、或金剛烷乙酸。業內已知包括親脂性部分之寡核苷酸、及製備該等寡核苷酸之方法,例如,美國專利第5,138,045號、第5,218,105號及第5,459,255號。
給定寡核苷酸中之所有位置並不需要經一致性修飾,且事實上可將上述修飾中之一種以上納入單一寡核苷酸中或甚至納入寡核苷酸內之單一核苷中。本發明亦包含係上文所定義嵌合寡核苷酸之寡核苷酸。
在另一實施例中,本發明之核酸分子與另一部分偶聯,該另一部分包含但不限於無鹼基核苷酸、聚醚、聚胺、聚醯胺、肽、碳水化合物、脂質、或聚烴化合物。彼等熟習此項技術者應認識到,該等分子可連接至在糖、鹼基或磷酸酯基團上之若干位置包括核酸分子之任一核苷酸中的一或多者上。
本發明所用之寡核苷酸可以便捷常規方式經由熟知固相合成技術來製備。包含Applied Biosystems在內之若干供貨商出售實施該合成之設備。亦可採用用於該合成之任一其他方式,熟習此項技術者熟知寡核苷酸之現行合成。亦熟知使用相似技術來製備諸如硫代磷酸酯及烷基化衍生物等其他寡核苷酸。業內亦熟知使用相似技術及市售經
修飾DNA合成核苷酸(amidite)及定孔玻璃(CPG)產品(例如經生物素、螢光素、吖啶或補骨脂素修飾之DNA合成核苷酸及/或CPG(可自Glen Research,Sterling,VA購得))來合成經螢光標記、經生物素化或經其他修飾之寡核苷酸,例如經膽固醇修飾之寡核苷酸。
根據本發明,使用修飾(例如使用LNA單體)來增強作用之功效、特異性及持續時間並拓寬寡核苷酸之投與途徑包括諸如MOE、ANA、FANA、PS等化學方式。此可藉由使用LNA單體代替當前寡核苷酸中之一些單體來達成。經LNA修飾之寡核苷酸可具有類似於母體化合物之尺寸或可較大或較佳地較小。較佳地,經LNA修飾之寡核苷酸含有小於約70%、更佳小於約60%、最佳小於約50%之LNA單體,且其尺寸介於約5與25個核苷酸、更佳約12與20個核苷酸之間。
較佳經修飾寡核苷酸主鏈包括但不限於硫代磷酸酯、對掌性硫代磷酸酯、二硫代磷酸酯、磷酸三酯、胺基烷基磷酸三酯、膦酸甲酯及其他膦酸烷基酯(包括膦酸3'-伸烷基酯及對掌性膦酸酯)、次膦酸酯、胺基磷酸酯(包括胺基磷酸3'-胺基酯及胺基磷酸胺基烷基酯)、硫羰基胺基磷酸酯、膦酸硫羰基烷基酯、硫羰基烷基磷酸三酯、及具有常見3'-5'鍵聯之硼烷磷酸酯、該等主鏈之2'-5'連接類似物、及彼等具有反極性者(其中相鄰核苷單元對之連接由3'-5'變為5'-3'或由2'-5'變為5'-2')。亦包含各種鹽、混合鹽及游離酸形式。
教示上述含磷鍵聯之代表性美國專利包括但不限於美國專利第3,687,808號、第4,469,863號、第4,476,301號、第5,023,243號、第5,177,196號、第5,188,897號、第5,264,423號、第5,276,019號、第5,278,302號、第5,286,717號、第5,321,131號、第5,399,676號、第5,405,939號、第5,453,496號、第5,455,233號、第5,466,677號、第5,476,925號、第5,519,126號、第5,536,821號、第5,541,306號、第5,550,111號、第5,563,253號、第5,571,799號、第5,587,361號、及第
5,625,050號,每一皆皆以引用方式併入本文中。
不含磷原子之較佳經修飾寡核苷酸主鏈具有藉由以下形成之主鏈:短鏈烷基或環烷基核苷間鍵聯、混合雜原子及烷基或環烷基核苷間鍵聯、或一或多個短鏈雜原子或雜環核苷間鍵聯。該等主鏈包括彼等具有嗎啉基鍵聯者(部分自核苷之糖部分形成);矽氧烷主鏈;硫化物、亞碸及碸主鏈;甲醯乙醯基及硫代甲醯乙醯基主鏈;亞甲基甲醯乙醯基及硫代甲醯乙醯基主鏈;含有烯烴之主鏈;胺基磺酸酯主鏈;亞甲基亞胺基及亞甲基肼基主鏈;磺酸酯及磺醯胺主鏈;醯胺主鏈;及其他具有混合N、O、S及CH2組成部分者。
教示上述寡核苷之代表性美國專利包括但不限於美國專利第5,034,506號、第5,166,315號、第5,185,444號、第5,214,134號、第5,216,141號、第5,235,033號、第5,264,562號、第5,264,564號、第5,405,938號、第5,434,257號、第5,466,677號、第5,470,967號、第5,489,677號、第5,541,307號、第5,561,225號、第5,596,086號、第5,602,240號、第5,610,289號、第5,602,240號、第5,608,046號、第5,610,289號、第5,618,704號、第5,623,070號、第5,663,312號、第5,633,360號、第5,677,437號、及第5,677,439號,每一皆皆以引用方式併入本文中。
在其他較佳寡核苷酸模擬物中,核苷酸單元中之糖及核苷間鍵聯(亦即主鏈)二者經新基團代替。保留鹼基單元以與適宜核酸靶化合物雜交。一種該寡聚化合物(已顯示具有極佳雜交性質之寡核苷酸模擬物)稱為肽核酸(PNA)。在PNA化合物中,寡核苷酸中之糖-主鏈經含醯胺主鏈、特定而言胺基乙基甘胺酸主鏈代替。保留核鹼基且其與主鏈中醯胺部分之氮雜氮原子直接或間接結合。教示PNA化合物之製備之代表性美國專利包括但不限於美國專利第5,539,082號、第5,714,331號、及第5,719,262號,每一者皆以引用方式併人本文中。
PNA化合物之其他教示內容可參見Nielsen等人,(1991)Science 254,1497-1500。
本發明一實施例係具有硫代磷酸酯主鏈之寡核苷酸及具有雜原子主鏈之寡核苷,且特定而言係上文所提及美國專利第5,489,677號中之-CH2-NH-O-CH2-、-CH2-N(CH3)-O-CH2-[稱為亞甲基(甲基亞胺基)或MMI主鏈]、-CH2-O-N(CH3)-CH2-、-CH2N(CH3)-N(CH3)CH2-及-O-N(CH3)-CH2-CH2-[其中天然磷酸二酯主鏈表示為-O-P-O-CH2-],及上文所提及美國專利第5,602,240號中之醯胺主鏈。亦較佳者係上文所提及美國專利第5,034,506號中之具有嗎啉基主鏈結構之寡核苷酸。
經修飾寡核苷酸亦可含有一或多個經取代糖部分。較佳寡核苷酸在2'位包括以下中之一者:OH;F;O-、S-或N-烷基、O-、S-或N-烯基;O-、S-或N-炔基;或O烷基-O-烷基,其中烷基、烯基及炔基可係經取代或未經取代之C1至C10烷基或C2至C10烯基及炔基。尤佳者係O(CH2)n OmCH3、O(CH2)n、OCH3、O(CH2)nNH2、O(CH2)nCH3、O(CH2)nONH2、及O(CH2nON(CH2)nCH3)2,其中n及m可為1至約10。其他較佳寡核苷酸在2'位包括以下中之一者:C1至C10低碳烷基、經取代低碳烷基、烷芳基、芳烷基、O-烷芳基或O-芳烷基、SH、SCH3、OCN、Cl、Br、CN、CF3、OCF3、SOCH3、SO2CH3、ONO2、NO2、N3、NH2、雜環烷基、雜環烷芳基、胺基烷基胺基、聚烷基胺基、經取代甲矽烷基、RNA裂解基團、受體基團、嵌入劑、改良寡核苷酸之藥物代謝動力學性質之基團、或改良寡核苷酸之藥效動力學性質之基團、及其他具有相似性質之取代基。較佳修飾包括2'-甲氧基乙氧基(2'-O-CH2CH2OCH3,亦稱為2'-O-(2-甲氧基乙基)或2'-MOE),亦即,烷氧基烷氧基。其他較佳經修飾包括2'-二甲基胺基氧基乙氧基(亦即,O(CH2)2ON(CH3)2基團,亦稱為2'-DMAOE,如下文實例中所述)、及2'-二甲基胺基乙氧基乙氧基(業
內亦稱為2'-O-二甲基胺基乙氧基乙基或2'-DMAEOE,亦即,2'-O-CH2-O-CH2-N(CH2)2)。
其他較佳修飾包括2'-甲氧基(2'-O-CH3)、2'-胺基丙氧基(2'-OCH2CH2CH2NH2)及2'-氟(2'-F)。亦可在寡核苷酸上之其他位置進行相似修飾,尤其係3'末端核苷酸上或2'-5'連接寡核苷酸中糖之3'位及5'末端核苷酸之5'位。寡核苷酸亦可具有糖模擬物,例如使用環丁基部分來代替戊呋喃糖基糖。教示該等經修飾糖結構之製備之代表性美國專利包括但不限於美國專利第4,981,957號、第5,118,800號、第5,319,080號、第5,359,044號、第5,393,878號、第5,446,137號、第5,466,786號、第5,514,785號、第5,519,134號、第5,567,811號、第5,576,427號、第5,591,722號、第5,597,909號、第5,610,300號、第5,627,053號、第5,639,873號、第5,646,265號、第5,658,873號、第5,670,633號、及第5,700,920號,每一者皆以引用方式併入本文中。
寡核苷酸亦可包括核鹼基(業內通常簡寫為「鹼基」)修飾或取代。本文所用之「未經修飾」或「天然」核苷酸包括嘌呤鹼基(腺嘌呤(A)及鳥嘌呤(G))及嘧啶鹼基(胸腺嘧啶(T)、胞嘧啶(C)及尿嘧啶(U))。經修飾核苷酸包括其他合成及天然核苷酸,例如5-甲基胞嘧啶(5-me-C)、5-羥甲基胞嘧啶、黃嘌呤、次黃嘌呤、2-胺基腺嘌呤、腺嘌呤及鳥嘌呤之6-甲基及其他烷基衍生物、腺嘌呤及鳥嘌呤之2-丙基及其他烷基衍生物、2-硫代尿嘧啶、2-硫代胸腺嘧啶及2-硫代胞嘧啶、5-鹵代尿嘧啶及胞嘧啶、5-丙炔基尿嘧啶及胞嘧啶、6-偶氮尿嘧啶、胞嘧啶及胸腺嘧啶、5-尿嘧啶(假尿嘧啶)、4-硫代尿嘧啶、8-鹵代、8-胺基、8-硫醇、8-硫代烷基、8-羥基及其他8-取代腺嘌呤及鳥嘌呤、5-鹵代、尤其5-溴、5-三氟甲基及其他5-取代尿嘧啶及胞嘧啶、7-甲基鳥嘌呤及7-甲基腺嘌呤、8-氮雜鳥嘌呤及8-氮雜腺嘌呤、7-去氮鳥嘌呤及7-去氮腺嘌呤及3-去氮鳥嘌呤及3-去氮腺嘌呤。
另外,核苷酸包括彼等揭示於美國專利第3,687,808號中者、彼等揭示於「The Concise Encyclopedia of Polymer Science And Engineering」,第858-859頁,Kroschwitz,J.I.編輯,John Wiley & Sons,1990中者、彼等由Englisch等人,「Angewandle Chemie,International Edition」,1991,30,第613頁揭示者、及彼等由Sanghvi,Y.S.,第15章,「Antisense Research and Applications」,第289-302頁,Crooke,S.T.及Lebleu,B.ea.,CRC Press,1993揭示者。某些該等核苷酸尤其用於增加本發明之寡聚化合物之結合親和力。該等核苷酸包括5-取代嘧啶、6-氮雜嘧啶及N-2、N-6及O-6取代嘌呤,包括2-胺基丙基腺嘌呤、5-丙炔基尿嘧啶及5-丙炔基胞嘧啶。已顯示5-甲基胞嘧啶取代可將核酸雙鏈體穩定性增加0.6-1.2℃(Sanghvi,Y.S.,Crooke,S.T.及Lebleu,B.編輯,「Antisense Research and Applications」,CRC Press,Boca Raton,1993,第276-278頁)且係當前較佳之鹼基取代,甚至更尤其在與2'-O甲氧基乙基糖修飾組合時。
教示上述經修飾核苷酸以及其他經修飾核苷酸之製備之代表性美國專利包括但不限於美國專利第3,687,808號、以及第4,845,205號、第5,130,302號、第5,134,066號、第5,175,273號、第5,367,066號、第5,432,272號、第5,457,187號、第5,459,255號、第5,484,908號、第5,502,177號、第5,525,711號、第5,552,540號、第5,587,469號、第5,596,091號、第5,614,617號、第5,750,692號、及第5,681,941號,每一者皆以引用方式併入本文中。
對本發明寡核苷酸之另一修飾涉及使一或多種可增強寡核苷酸之活性、細胞分佈或細胞攝取之部分或偶聯物以化學方式連接至寡核苷酸。
該等部分包括但不限於脂質部分(例如膽固醇部分)、膽酸、硫醚(例如,己基-S-三苯甲基硫醇)、硫代膽固醇、脂肪族鏈(例如,十二
烷二醇或十一烷基殘基)、磷脂(例如,二-十六烷基-外消旋-甘油或三乙基銨1,2-二-O-十六烷基-外消旋-甘油-3-H-膦酸酯)、聚胺或聚乙二醇鏈、或金剛烷乙酸、棕櫚基部分、或十八胺或己基胺基-羰基-氧基膽固醇部分。
教示該等寡核苷酸偶聯物之製備之代表性美國專利包括但不限於美國專利第4,828,979號、第4,948,882號、第5,218,105號、第5,525,465號、第5,541,313號、第5,545,730號、第5,552,538號、第5,578,717號、第5,580,731號、第5,580,731號、第5,591,584號、第5,109,124號、第5,118,802號、第5,138,045號、第5,414,077號、第5,486,603號、第5,512,439號、第5,578,718號、第5,608,046號、第4,587,044號、第4,605,735號、第4,667,025號、第4,762,779號、第4,789,737號、第4,824,941號、第4,835,263號、第4,876,335號、第4,904,582號、第4,958,013號、第5,082,830號、第5,112,963號、第5,214,136號、第5,082,830號、第5,112,963號、第5,214,136號、第5,245,022號、第5,254,469號、第5,258,506號、第5,262,536號、第5,272,250號、第5,292,873號、第5,317,098號、第5,371,241號、第5,391,723號、第5,416,203號、第5,451,463號、第5,510,475號、第5,512,667號、第5,514,785號、第5,565,552號、第5,567,810號、第5,574,142號、第5,585,481號、第5,587,371號、第5,595,726號、第5,597,696號、第5,599,923號、第5,599,928號、及第5,688,941號,每一者皆以引用方式併入本文中。
藥物研究:亦可將本發明化合物加至藥物研究及靶驗證之區域中。本發明涵蓋本文所鑑別化合物及較佳靶區段在藥物研究中之用途,該藥物研究試圖闡釋PAR4多核苷酸與疾病狀態、表現型、或病狀之間所存在之關係。該等方法包含檢測或調節PAR4多核苷酸,其包括使試樣、組織、細胞、或有機體與本發明化合物接觸,在治療後
某一時間量測PAR4多核苷酸之核酸或蛋白質含量及/或相關表現型或化學端點,及視需要比較量測值與未處理試樣或經本發明中另一化合物處理之試樣。該等方法亦可與其他實驗並行或組合實施以測定用於靶驗證過程之未知基因的功能,或用以測定特定基因產物作為用於治療或預防特定疾病、病狀、或表現型之靶的有效性。
可藉由直接檢測細胞或有機體中核酸之存在來評價外源核酸向宿主細胞或有機體中的轉移。該檢測可藉由業內熟知之若干方法來達成。例如,可藉由南方印跡或藉由聚合酶鏈反應(PCR)技術使用特異性擴增與核酸有關之核苷酸序列之引物來檢測外源核酸的存在。亦可使用包含基因表現分析在內之習用方法來量測外源核酸之表現。舉例而言,可使用北方印跡及逆轉錄PCR(RT-PCR)來檢測及量化自外源核酸產生之mRNA。
亦可藉由量測酶活性或報導子蛋白活性來檢測外源核酸中RNA之表現。舉例而言,可根據靶核酸表現之降低或增加來間接量測反股調節活性,從而指示外源核酸在效應子RNA中產生。基於序列保守性,可設計引物並用於擴增靶基因之編碼區域。最初,可使用來自每一基因之最高表現編碼區域來建立對照基因模型,但可使用任一編碼或非編碼區域。藉由將每一編碼區域插入報導子編碼區域及其poly(A)信號之間來組裝每一對照基因。該等質粒將產生在基因上游部分具有報導子基因且在3'非編碼區域中具有潛在RNAi靶之mRNA。藉由調節報導子基因來分析個別反股寡核苷酸之有效性。用於本發明方法中之報導子基因包含乙醯羥酸合酶(AHAS)、鹼性磷酸酶(AP)、β半乳糖苷酶(LacZ)、β葡糖醛酸糖苷酶(GUS)、氯黴素乙醯轉移酶(CAT)、綠色螢光蛋白(GFP)、紅色螢光蛋白(RFP)、黃色螢光蛋白(YFP)、青色螢光蛋白(CFP)、辣根過氧化物酶(HRP)、螢光素酶
(Luc)、胭脂鹼合酶(NOS)、章魚肉鹼合酶(OCS)、及其衍生物。可使用賦予以下物質抗性之多種可選擇標記物:胺苄西林(ampicillin)、博來黴素(bleomycin)、氯黴素(chloramphenicol)、慶大黴素(gentamycin)、潮黴素(hygromycin)、卡那黴素(kanamycin)、林可黴素(lincomycin)、甲胺喋呤(methotrexate)、草胺膦(phosphinothricin)、嘌呤黴素(puromycin)、及四環素(tetracycline)。測定報導子基因之調節的方法在業內已眾所周知,且包含但不限於螢光方法(例如螢光光譜法、螢光活化細胞分選(FACS)、螢光顯微術)、抗生素抗性測定。
可使用彼等熟習此項技術者已知及闡述於本文其他處之方法來分析PAR4蛋白及mRNA表現。舉例而言,可使用諸如ELISA等免疫分析來量測蛋白質含量。PAR4 ELISA分析套組市面有售,例如,購自R&D Systems(Minneapolis,MN)。
在實施例中,藉由與對照試樣中之PAR4表現進行比較來評估使用本發明反股寡核苷酸處理之試樣(例如,活體內或活體外中之細胞或組織)中的PAR4表現(例如,mRNA或蛋白質)。舉例而言,可使用彼等熟習此項技術者已知之方法來對蛋白質或核酸之表現與模擬處理或未處理試樣進行比較。另一選擇為,可端視期望資訊來比較所處理試樣與對照反股寡核苷酸(例如,具有經改變或不同序列者)。在另一實施例中,可使用經處理試樣與未處理試樣中不同核酸(包含研究者認為適宜之任一標準,例如,持家基因)表現之差異來比較經處理試樣與未處理試樣中PAR4蛋白質或核酸表現之差異。
可根據需要(例如)以比率或份數形式來表示所觀察之差異以用於與對照進行比較。在實施例中,相對於未處理試樣或經對照核酸處理之試樣,經本發明反股寡核苷酸處理之試樣中PAR4 mRNA或蛋白質之含量增加或降低約1.25倍至約10倍或更高。在實施例中,PAR4 mRNA或蛋白質之含量增加或降低至少約1.25倍、至少約1.3倍、至少
約1.4倍、至少約1.5倍、至少約1.6倍、至少約1.7倍、至少約1.8倍、至少約2倍、至少約2.5倍、至少約3倍、至少約3.5倍、至少約4倍、至少約4.5倍、至少約5倍、至少約5.5倍、至少約6倍、至少約6.5倍、至少約7倍、至少約7.5倍、至少約8倍、至少約8.5倍、至少約9倍、至少約9.5倍、或至少約10倍或更高。
本發明化合物可用於診斷、治療、及預防,且可用作套組之研究試劑及組份。另外,彼等熟習此項技術者通常使用能夠以強烈特異性抑制基因表現之反股寡核苷酸來闡釋特定基因之功能或區別生物路徑之各個成員的功能。
對於在套組及診斷及各種生物系統中之應用而言,本發明化合物(單獨或與其他化合物或治療劑組合)可用作差值及/或組合分析中之工具以闡釋細胞及組織內所表現基因之一部分或整個互補體的表現模式。
本文所用之術語「生物系統」或「系統」定義為表現、或使其足以表現PAR4基因產物的任一有機體、細胞、細胞培養物或組織。該等系統包含但不限於人類、轉基因動物、細胞、細胞培養物、組織、異種移植物、移植物及其組合。
根據一非限制性實例,對經一或多種反股化合物處理之細胞或組織內的表現模式與未經反股化合物處理之對照細胞或組織進行比較,且分析所得模式關於(例如)疾病相關性、信號傳導路徑、細胞定位、表現程度、所檢驗基因之尺寸、結構或功能之基因表現的差異程度。該等分析可在經刺激或未經刺激細胞中且在影響表現模式之其他化合物存在或不存在下實施。
業內已知之基因表現分析之方法實例包含DNA陣列或微陣列、SAGE(基因表現之系列分析)、READS(消化cDNA之限制性酶擴增)、
TOGA(總體基因表現分析)、蛋白質陣列及蛋白組學、已表現序列標誌(EST)測序、消減RNA指紋技術(SuRF)、消減選殖、差異顯示(DD)、比較基因組雜交、FISH(螢光原位雜交)技術及質譜方法。
本發明化合物可用於研究及診斷中,此乃因該等化合物可與編碼PAR4之核酸雜交。舉例而言,在如本文所揭示可用作有效PAR4調節劑之效率及條件下雜交之寡核苷酸在分別有利於基因擴增或檢測之條件下係有效引物或探針。該等引物及探針可用於需要特異性檢測編碼PAR4之核酸分子的方法中及擴增該等核酸分子以用於檢測或用於其他PAR4研究。本發明之反股寡核苷酸(尤其引物及探針)與編碼PAR4之核酸的雜交可藉由業內已知方式進行檢測。該等方式可包含使酶與寡核苷酸偶聯、放射性標記寡核苷酸、或任一其他適宜檢測方式。亦可製造使用該等檢測方式檢測試樣中之PAR4含量的套組。
彼等熟習此項技術者亦在治療應用中利用反股化合物之特異性及敏感性。反股化合物已用作治療部分來治療動物(包含人類)之疾病狀態。反股寡核苷酸藥物已安全且有效地投與人類且當前正實施許多臨床試驗。由此確定,反股化合物可為可經設置用於治療細胞、組織及動物(尤其人類)之治療方案中的有用治療方式。
在治療時,藉由投與本發明反股化合物來治療懷疑患有可藉由調節PAR4多核苷酸之表現進行治療之疾病或病症的動物(較佳係人類)。舉例而言,在一非限制性實施例中,該等方法包括向需要治療之動物投與治療有效量之PAR4調節劑之步驟。本發明之PAR4調節劑可有效調節PAR4之活性或調節PAR4蛋白質之表現。在一實施例中,與對照相比,使PAR4在動物中之活性或表現抑制約10%。較佳地,使PAR4在動物中之活性或表現抑制約30%。更佳地,使PAR4在動物中之活性或表現抑制50%或更高。因此,與對照相比,寡聚化合物可將PAR4 mRNA之表現調節至少10%、至少50%、至少25%、至少30%、
至少40%、至少50%、至少60%、至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少98%、至少99%、或100%。
在一實施例中,與對照相比,使PAR4在動物中之活性或表現抑制約10%。較佳地,使PAR4在動物中之活性或表現增加約30%。更佳地,使PAR4在動物中之活性或表現增加50%或更高。因此,與對照相比,寡聚化合物可將PAR4 mRNA之表現調節至少10%、至少50%、至少25%、至少30%、至少40%、至少50%、至少60%、至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少98%、至少99%、或100%。
舉例而言,可量測動物之血清、血液、脂肪組織、肝或任一其他體液、組織或器官中PAR4之表現的減小。較佳地,所分析之該等流體、組織或器官內所含之細胞含有編碼PAR4肽及/或PAR4蛋白質本身的核酸分子。
可藉由將有效量之本發明化合物添加至適宜醫藥上可接受之稀釋劑或載劑中來將該化合物用於醫藥組合物中。本發明之化合物用途及方法亦可用於預防目的。
對本發明寡核苷酸之另一修飾涉及使一或多種可增強寡核苷酸之活性、細胞分佈或細胞攝取之部分或偶聯物以化學方式連接至寡核苷酸。該等部分或偶聯物可包含共價結合至諸如一級或二級羥基等功能基團之偶聯基團。本發明之偶聯基團包含嵌入劑、報導子分子、聚胺、聚醯胺、聚乙二醇、聚醚、增強寡聚物之藥效動力學性質之基團、及增強寡聚物之藥物代謝動力學性質之基團。典型偶聯基團包含膽固醇、脂質、磷脂、生物素、吩嗪、葉酸酯、菲啶、蒽醌、吖啶、螢光素、若丹明(rhodamine)、香豆素、及染料。在本發明之上下文中,增強藥效動力學性質之基團包含可改良攝取、增強降解抗性、及
/或增強與靶核酸之序列特異性雜交的基團。在本發明之上下文中,增強藥物代謝動力學性質之基團包含可改良本發明化合物之攝取、分佈、代謝或分泌的基團。代表性偶聯基團揭示於1992年10月23日提出申請之國際專利申請案第PCT/US92/09196號、及美國專利第6,287,860號中,其以引用方式併入本文中。偶聯部分包含但不限於脂質部分(例如膽固醇部分)、膽酸、硫醚(例如,己基-5-三苯甲基硫醇)、硫代膽固醇、脂肪族鏈(例如,十二烷二醇或十一烷基殘基)、磷脂(例如,二-十六烷基-外消旋-甘油或三乙基銨1,2-二-O-十六烷基-外消旋-甘油-3-H膦酸酯)、聚胺或聚乙二醇鏈、或金剛烷乙酸、棕櫚基部分、或十八胺或己基胺基-羰基-氧基膽固醇部分。本發明之寡核苷酸亦可偶聯至活性藥物物質,例如,阿司匹林(aspirin)、華法林(warfarin)、保泰松(phenylbutazone)、布洛芬(ibuprofen)、舒洛芬(suprofen)、芬布芬(fenbufen)、酮洛芬(ketoprofen)、(S)-(+)-普拉洛芬((S)-(+)-pranoprofen)、卡洛芬(carprofen)、丹肌胺酸(dansylsarcosine)、2,3,5-三碘苯甲酸、氟芬那酸(flufenamic acid)、亞葉酸、苯并噻二嗪、氯噻嗪、二氮呯、吲哚美辛(indomethicin)、巴比妥酸鹽、頭孢菌素(cephalosporin)、磺胺藥、抗糖尿病藥、抗菌劑或抗生素。
教示該等寡核苷酸偶聯物之製備之代表性美國專利包含但不限於美國專利第4,828,979號、第4,948,882號、第5,218,105號、第5,525,465號、第5,541,313號、第5,545,730號、第5,552,538號、第5,578,717號、第5,580,731號、第5,580,731號、第5,591,584號、第5,109,124號、第5,118,802號、第5,138,045號、第5,414,077號、第5,486,603號、第5,512,439號、第5,578,718號、第5,608,046號、第4,587,044號、第4,605,735號、第4,667,025號、第4,762,779號、第4,789,737號、第4,824,941號、第4,835,263號、第4,876,335號、第
4,904,582號、第4,958,013號、第5,082,830號、第5,112,963號、第5,214,136號、第5,082,830號、第5,112,963號、第5,214,136號、第5,245,022號、第5,254,469號、第5,258,506號、第5,262,536號、第5,272,250號、第5,292,873號、第5,317,098號、第5,371,241號、第5,391,723號、第5,416,203號、第5,451,463號、第5,510,475號、第5,512,667號、第5,514,785號、第5,565,552號、第5,567,810號、第5,574,142號、第5,585,481號、第5,587,371號、第5,595,726號、第5,597,696號、第5,599,923號、第5,599,928號及第5,688,941號。
本發明化合物亦可與其他分子、分子結構或化合物混合物(例如,脂質體、靶向受體之分子、經口、直腸、局部或其他調配物)混合、囊封、偶聯或以其他方式結合以有助於攝取、分佈及/或吸收。教示該等有助於攝取、分佈及/或吸收之調配物之製備的代表性美國專利包含但不限於美國專利第5,108,921號、第5,354,844號、第5,416,016號、第5,459,127號、第5,521,291號、第5,543,165號、第5,547,932號、第5,583,020號、第5,591,721號、第4,426,330號、第4,534,899號、第5,013,556號、第5,108,921號、第5,213,804號、第5,227,170號、第5,264,221號、第5,356,633號、第5,395,619號、第5,416,016號、第5,417,978號、第5,462,854號、第5,469,854號、第5,512,295號、第5,527,528號、第5,534,259號、第5,543,152號、第5,556,948號、第5,580,575號、及第5,595,756號,每一者皆以引用方式併入本文中。
儘管為調節靶表現及/或功能不需要在載體背景中投與反股寡核苷酸,但本發明實施例係關於用於表現反股寡核苷酸之表現載體構成物,其包括啟動子、雜合啟動子基因序列且具有較強組成型啟動子活性,或可在期望情形下誘導之啟動子活性。
在一實施例中,本發明實踐涉及使用適宜核酸遞送系統投與上述反股寡核苷酸中之至少一者。在一實施例中,該系統包含可操作地連接至多核苷酸之非病毒載體。該等非病毒載體之實例包含僅寡核苷酸(例如,SEQ ID NO:3至9之任一者或多者)或與適宜蛋白質、多糖或脂質調配物之組合。
另外,適宜核酸遞送系統包含病毒載體,其通常係來自腺病毒、腺病毒相關病毒(AAV)、輔助細胞依賴性腺病毒、逆轉錄病毒、或日本脂質體血凝病毒(HVJ)複合物中之至少一者之序列。較佳地,病毒載體包括可操作地連接至多核苷酸之強真核生物啟動子(例如,巨細胞病毒(CMV)啟動子)。
另外,較佳載體包含病毒載體、融合蛋白及化學偶聯物。逆轉錄載體包含Moloney小鼠白血病病毒及HIV基病毒。一種較佳HIV基病毒載體包括至少兩個載體,其中gag及pol基因來自HIV基因組且env基因來自另一病毒。DNA病毒載體較佳。該等載體包含pox載體(例如正痘病毒或鳥痘病毒載體)、疱疹病毒載體(例如單純疱疹I病毒(HSV)載體)、腺病毒載體及腺相關病毒載體。
本發明之反股化合物涵蓋任一醫藥上可接受之鹽、酯、或該等酯之鹽、或在投與動物(包含人類)後能夠提供(直接或間接)生物活性代謝物或其殘基的任一其他化合物。
術語「醫藥上可接受之鹽」係指本發明化合物之生理上及醫藥上可接受之鹽:亦即,可保留母體化合物之期望生物活性且並不賦予其不期望毒理學效應之鹽。對於寡核苷酸而言,醫藥上可接受之鹽及其應用之較佳實例進一步闡述於美國專利第6,287,860號中,其以引用方式併入本文中。
本發明亦包含含有本發明之反股化合物之醫藥組合物及調配物。端視期望局部抑或全身性治療及擬治療區域,本發明之醫藥組合
物可以各種方式投與。投與可為局部(包含眼部投與及投與黏膜,包含陰道及直腸遞送)、肺部(例如,藉由吸入或噴射粉末或氣溶膠,包含藉由霧化器);氣管內、鼻內、表皮及經皮、經口或非經腸投與。非經腸投與包含靜脈內、動脈內、皮下、腹膜腔內或肌內注射或輸注;或顱內(例如,鞘內或心室內)投與。
為治療中樞神經系統中之組織,可藉由(例如)注射或輸注至腦脊髓流體中來進行投與。反股RNA在腦脊髓流體中之投與闡述於(例如)美國專利申請公開案第2007/0117772號之「Methods for slowing familial ALS disease progression」中,其全部內容以引用方式併入本文中。
在意欲將本發明之反股寡核苷酸投與中樞神經系統之細胞中時,可投與一或多種能夠促進標題反股寡核苷酸滲透經過血腦障壁之藥劑。可在(例如)內嗅皮層或海馬區中進行注射。藉由向肌肉組織中之運動神經元投與腺病毒載體來遞送神經營養因子闡述於(例如)美國專利第6,632,427號之「Adenoviral-vector-mediated gene transfer into medullary motor neurons」中,其以引用方式併入本文中。業內已知將載體直接遞送至腦(例如,紋狀體、丘腦、海馬區、或黑質)中並闡述於(例如)美國專利第6,756,523號之「Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain」中,其以引用方式併入本文中。可藉由注射快速投與或經一定時間藉由緩慢輸注或投與緩釋調配物進行投與。
標題反股寡核苷酸亦可與提供期望醫藥或藥效動力學性質之藥劑連接或偶聯。舉例而言,反股寡核苷酸可與業內已知促進在血腦障壁中之滲透或輸送之任一物質(例如鐵傳遞蛋白受體之抗體)偶合,並藉由靜脈內注射投與。反股化合物可與病毒載體連接,該病毒載體可(例如)使反股化合物更有效及/或增加反股化合物在血腦障壁中之輸
送。亦可藉由(例如)輸注以下物質來破壞滲透性血腦障壁:糖,包含但不限於內消旋赤藻糖醇、木糖醇、D(+)半乳糖、D(+)乳糖、D(+)木糖、衛矛醇、肌-肌醇、L(-)果糖、D(-)甘露醇、D(+)葡萄糖、D(+)阿拉伯糖、D(-)阿拉伯糖、纖維二糖、D(+)麥芽糖、D(+)棉子糖、L(+)鼠李糖、D(+)蜜二糖、D(-)核糖、核糖醇、D(+)阿糖醇、L(-)阿糖醇、D(+)岩藻糖、L(-)岩藻糖、D(-)來蘇糖、L(+)來蘇糖、及L(-)來蘇糖;或胺基酸,包含但不限於麩胺醯胺、離胺酸、精胺酸、天門冬醯胺、天門冬胺酸、半胱胺酸、麩胺酸、甘胺酸、組胺酸、亮胺酸、甲硫胺酸、苯丙胺酸、脯胺酸、絲胺酸、蘇胺酸、酪胺酸、擷胺酸、及牛磺酸。用於增強血腦障壁滲透之方法及材料闡述於(例如)美國專利第4,866,042號之「Method for the delivery of genetic material across the blood brain barrier」、第6,294,520號之「Material for passage through the blood-brain barrier」及第6,936,589號之「Parenteral delivery systems」中,其全部內容皆以引用方式併入本文中。
標題反股化合物可與其他分子、分子結構或化合物混合物(例如,脂質體、靶向受體之分子、經口、直腸、局部或其他調配物)混合、囊封、偶聯或以其他方式結合以有助於攝取、分佈及/或吸收。舉例而言,陽離子型脂質可包含於調配物中以促進寡核苷酸攝取。一種顯示可促進攝取之該組合物係LIPOFECTIN(購自GIBCO-BRL,Bethesda,MD)。
據信,至少一個2'-O-甲氧基乙基修飾之寡核苷酸尤其可用於經口投與。用於局部投與之醫藥組合物及調配物可包含經皮貼片、軟膏、洗劑、乳膏、凝膠、滴劑、栓劑、噴霧劑、液體及粉末。可能需要或期望習用醫藥載劑、水性、粉末或油性基質、增稠劑及諸如此類。亦可使用包覆避孕套、手套及諸如此類。
可便利地以單位劑型呈現之本發明醫藥調配物可根據醫藥工業
中熟知之習用技術製得。該等技術包含使活性成份與醫藥載劑或賦形劑結合之步驟。一般而言,調配物可藉由使活性成份與液體載劑或微細固體載劑或二者均勻且充分結合且然後(若必要)使該產物成型來製備。
可將本發明組合物調配成許多可能劑型中之任一者,例如但不限於錠劑、膠囊、凝膠膠囊、液體糖漿、軟質凝膠、栓劑、及灌腸劑。本發明組合物亦可調配成存於水性、非水性或混合介質中之懸浮液。水性懸浮液可進一步含有可增加懸浮液之黏度之物質,其包含(例如)羧甲基纖維素鈉、山梨糖醇及/或右旋糖酐。懸浮液亦可含有穩定劑。
本發明之醫藥組合物包含但不限於溶液、乳液、發泡體及含有脂質體之調配物。本發明之醫藥組合物及調配物可包括一或多種滲透增強劑、載劑、賦形劑或其他活性或無活性成份。
乳液通常係一種液體分散於另一液滴形式液體(直徑經常超過0.1μm)的異質系統。乳液除分散相外亦可含有額外組份、及可呈現為存於水相、油相中之溶液形式或自身作為分離相的活性藥物。本發明一實施例包含微乳液。乳液及其應用在業內已眾所周知且進一步闡述於美國專利第6,287,860號中。
本發明調配物包含脂質體調配物。本發明所用之術語「脂質體」意指由佈置於一或多個球形雙層中之兩親性脂質組成的囊泡。脂質體係單層或多層囊泡,其具有自親脂性材料形成之膜及含有擬遞送組合物之水性內部結構。陽離子型脂質體係帶正電之脂質體,據信其可與帶負電之DNA分子相互作用以形成穩定複合物。對pH敏感或帶負電之脂質體據信可捕獲DNA而非與其複合。陽離子型及非陽離子型脂質體皆可用於向細胞遞送DNA。
脂質體亦包含「空間穩定」之脂質體,本文所用之該術語係指
包括一或多種特定脂質之脂質體。在納入脂質體中時,該等特定脂質會產生相對於缺乏該等特定脂質之脂質體具有增強之循環壽命的脂質體。空間穩定脂質體之實例係彼等脂質體中形成囊泡之脂質部分包括一或多種糖脂或衍生自一或多種親水性聚合物(例如聚乙二醇(PEG)部分)者。脂質體及其應用進一步闡述於美國專利第6,287,860號中。
本發明之醫藥調配物及組合物亦可包含表面活性劑。表面活性劑在藥物產物、調配物及乳液中之應用在業內已眾所周知。表面活性劑及其應用進一步闡述於美國專利第6,287,860號中,其以引用方式併入本文中。
在一實施例中,本發明採用各種滲透增強劑來實現核酸、尤其寡核苷酸之有效遞送。除有助於非親脂性藥物在細胞膜中之擴散外,滲透增強劑亦增強親脂性藥物之滲透性。滲透增強劑可歸類為5大類中之一者:亦即,表面活性劑、脂肪酸、膽汁鹽、螯合劑、及非螯合性非表面活性劑。滲透增強劑及其應用進一步闡述於美國專利第6,287,860號中,其以引用方式併入本文中。
熟習此項技術者應認識到,調配物通常根據其預期應用(亦即投與途徑)來進行設計。
用於局部投與之較佳調配物包含彼等本發明寡核苷酸與局部遞送劑混合者,該局部遞送劑係(例如)脂質、脂質體、脂肪酸、脂肪酸酯、類固醇、螯合劑及表面活性劑。較佳脂質及脂質體包含中性脂質及脂質體(例如二油醯基-磷脂醯基DOPE乙醇胺、二肉豆蔻醯基磷脂醯基膽鹼DMPC、二硬脂醯基磷脂醯基膽鹼)、負脂質及脂質體(例如二肉豆蔻醯基磷脂醯基甘油DMPG)及陽離子型脂質及脂質體(例如二油醯基四甲基胺基丙基DOTAP及二油醯基-磷脂醯基乙醇胺DOTMA)。
對於局部或其他投與而言,本發明之寡核苷酸可囊封於脂質體
內或可與其形成複合物(尤其陽離子型脂質體)。另一選擇為,寡核苷酸可與脂質、尤其陽離子型脂質複合。較佳脂肪酸及酯、其醫藥上可接受之鹽、及其應用進一步闡述於美國專利第6,287,860號中。
用於經口投與之組合物及調配物包含粉末或粒子、微顆粒、奈米顆粒、存於水或非水性介質中之懸浮液或溶液、膠囊、凝膠膠囊、藥囊、錠劑或微錠劑。可能期望使用增稠劑、矯味劑、稀釋劑、乳化劑、分散助劑或黏合劑。較佳口服調配物係彼等本發明寡核苷酸與一或多種滲透增強劑、表面活性劑及螯合劑聯合投與者。較佳表面活性劑包含脂肪酸及/或其酯或鹽、膽汁酸及/或其鹽。較佳膽汁酸/鹽及脂肪酸及其應用進一步闡述於美國專利第6,287,860號中,其以引用方式併入本文中。亦較佳者係滲透增強劑之組合,例如,脂肪酸/鹽與膽汁酸/鹽之組合。尤佳之組合係月桂酸之鈉鹽、癸酸及UDCA。其他滲透增強劑包含聚氧乙烯-9-月桂基醚、聚氧乙烯-20-鯨蠟基醚。本發明之寡核苷酸可以粒子形式(包含噴霧乾燥顆粒、或經複合以形成微顆粒或奈米顆粒)經口遞送。寡核苷酸複合劑及其應用進一步闡述於美國專利第6,287,860號中,其以引用方式併入本文中。
用於非經腸、鞘內或心室內投與之組合物及調配物可包含亦可含有緩衝劑、稀釋劑及其他適宜添加劑之無菌水溶液,該等其他適宜添加劑係(例如)但不限於滲透增強劑、載劑化合物及其他醫藥上可接受之載劑或賦形劑。
本發明某些實施例提供含有一或多種寡聚化合物及一或多種藉由非反股機制發揮作用之其他化學治療劑之醫藥組合物。該等化學治療劑之實例包含但不限於癌症化學治療藥物,例如柔紅黴素(daunorubicin)、道諾黴素(daunomycin)、更生黴素(dactinomycin)、多柔比星(doxorubicin)、表柔比星(epirubicin)、伊達比星(idarubicin)、依索比星(esorubicin)、博來黴素、馬磷醯胺(mafosfamide)、異環磷醯
胺(ifosfamide)、胞嘧啶阿糖核苷(cytosine arabinoside)、亞硝脲氮芥(bischloroethyl-nitrosurea)、白消安(busulfan)、絲裂黴素C(mitomycin C)、放線菌素D(actinomycin D)、光輝黴素(mithramycin)、潑尼松(prednisone)、羥孕酮(hydroxyprogesterone)、睪酮(testosterone)、他莫昔芬(tamoxifen)、達卡巴嗪(dacarbazine)、丙卡巴肼(procarbazine)、六甲三聚氰胺(hexamethylmelamine)、五甲三聚氰胺(pentamethylmelamine)、米托蒽醌(mitoxantrone)、安吖啶(amsacrine)、苯丁酸氮芥(chlorambucil)、環己亞硝脲(methylcyclohexylnitrosurea)、氮芥(nitrogen mustards)、美法侖(melphalan)、環磷醯胺(cyclophosphamide)、6-巰嘌呤(6-mercaptopurine)、6-硫鳥嘌呤(6-thioguanine)、阿糖胞苷(cytarabine)、5-氮雜胞苷(5-azacytidine)、羥基脲(hydroxyurea)、噴司他丁(deoxycoformycin)、4-羥基過氧環磷醯胺(4-hydroxyperoxycyclo-phosphoramide)、5-氟尿嘧啶(5-fluorouracil)(5-FU)、5-氟去氧尿苷(5-fluorodeoxyuridine)(5-FUdR)、甲胺喋呤(MTX)、秋水仙鹼(colchicines)、紫杉醇(taxol)、長春新鹼(vincristine)、長春鹼(vinblastine)、依託泊甙(etoposide)(VP-16)、三甲曲沙(trimetrexate)、伊立替康(irinotecan)、托泊替坎(topotecan)、吉西他濱(gemcitabine)、替尼泊甙(teniposide)、順鉑(cisplatin)及己烯雌酚(diethylstilbestrol)(DES)。在與本發明化合物一起使用時,該等化學治療劑可單獨(例如,5-FU及寡核苷酸)、依序(例如,5-FU及寡核苷酸,隨後在一定時間之後係MTX及寡核苷酸)、或與一或多種其他該等化學治療劑組合(例如,5-FU、MTX及寡核苷酸,或5-FU、放射療法及寡核苷酸)使用。抗炎藥(包含但不限於非類固醇抗炎藥及皮質類固醇,以及抗病毒藥,包含但不限於利巴韋林(ribivirin)、阿糖腺苷(vidarabine)、阿昔洛韋(acyclovir)及更昔洛韋(ganciclovir))亦可組合
於本發明組合物中。反股化合物及其他非反股藥物之組合亦屬於本發明範圍內兩種或更多種組合之化合物可一起或依序使用。
在另一相關實施例中,本發明組合物可含有一或多種靶向第一核酸之反股化合物(尤其寡核苷酸)及一或多種靶向第二核酸靶之額外反股化合物。舉例而言,第一靶可為PAR4之特定反股序列,且第二靶可為來自另一核苷酸序列之區域。另一選擇為,本發明組合物可含有兩種或更多種靶向同一PAR4核酸靶之不同區域的反股化合物。反股化合物之諸多實例闡釋於本文中且其他實例可選自業內已知之適宜化合物。兩種或更多種組合之化合物可一起或依序使用。
據信,彼等熟習此項技術者應瞭解治療性組合物之調配及其隨後之投與(投藥)。投藥取決於欲治療疾病狀態之嚴重程度及反應性,其中治療過程可持續數天至數月,或直至實現治癒或減輕疾病狀態為止。可藉由量測患者體內之藥物積累來計算最適投藥方案。熟習此項技術者可容易地確定最適劑量、投藥方法及重複速率。最適劑量可端視個別寡核苷酸之相對功效而有所變化,且通常可基於發現在活體外及活體內動物模型中有效之EC50進行估計。一般而言,劑量為0.01μg/kg體重至100g/kg體重,且可每日、每週、每月或每年給予一次或更多次,或甚至每2至20年給予一次。熟習此項技術者可容易地基於體液或組織中藥物之所量測滯留時間及濃度來估計投藥的重複速率。成功治療後,可期望使患者維持該療法以預防疾病狀態復發,其中以介於0.01μg/kg體重至100g/kg體重之間之維持劑量投與寡核苷酸,且每日投與一次或更多次至每20年投與一次。
在實施例中,使用以下劑量之藥物來治療患者:至少約1mg/kg體重、至少約2mg/kg體重、至少約3mg/kg體重、至少約4mg/kg體重、至少約5mg/kg體重、至少約6mg/kg體重、至少約7mg/kg體重、
至少約8mg/kg體重、至少約9mg/kg體重、至少約10mg/kg體重、至少約15mg/kg體重、至少約20mg/kg體重、至少約25mg/kg體重、至少約30mg/kg體重、至少約35mg/kg體重、至少約40mg/kg體重、至少約45mg/kg體重、至少約50mg/kg體重、至少約60mg/kg體重、至少約70mg/kg體重、至少約80mg/kg體重、至少約90mg/kg體重、或至少約100mg/kg體重。反股寡核苷酸之某些注射劑量闡述於(例如)美國專利第7,563,884號之「Antisense modulation of PTP1B expression」中,其全部內容以引用方式併入本文中。
儘管上文已闡述本發明之各個實施例,然而,應理解,該等實施例僅係以實例方式而非限制方式提供。可根據本文之揭示內容對所揭示實施例作出諸多改變,此並不背離本發明之精神或範圍。因此,本發明之廣度及範圍不應受上述實施例中之任一者限制。
本文所提及之所有文件皆以引用方式併入本文中。出於所有目的,在本申請案中引用之所有出版物及專利文件皆係以引用方式併入,其併入程度如同每一個別出版物或專利文件係單獨闡述一般。對於此文件中引用之各個參考文獻,申請者不承認任一特定參考文獻係其發明之「先前技術」。本發明組合物及方法之實施例闡釋於下列實例中。
以下非限制性實例用於闡釋本發明之所選實施例。應瞭解,所示組份之元素之比率變化及代替物已為彼等熟習此項技術者所明瞭且屬於本發明實施例之範圍內。
如上所述,術語「對…具有特異性之寡核苷酸」或「靶向…之寡核苷酸」係指具有如下序列之寡核苷酸:(i)能夠與靶向基因之一部分
形成穩定複合物,或(ii)能夠與靶向基因之mRNA轉錄本之一部分形成穩定雙鏈體。
藉由使用電腦程式(例如IDT AntiSense Design,IDT OligoAnalyzer)來促進適當寡核苷酸之選擇,該等電腦程式自動鑑別每一給定序列中之19-25個核苷酸之子序列,該等子序列與靶多核苷酸序列形成雜合體且具有期望熔融溫度(通常為50-60℃),且不會形成自身二聚體或其他複雜二級結構。
藉由使用自動對凖核酸序列並指示一致性或同源性區域之電腦程式來進一步促進適當寡核苷酸的選擇。使用該等程式藉由(例如)搜索諸如GenBank等數據庫或藉由對PCR產物測序來比較所獲得的核酸序列。對來自給定基因組中一定範圍基因及基因間區域之核酸序列進行比較使得可選擇對目標基因顯示適當特異性程度的核酸序列。該等程序使得可選擇對給定基因組中之靶核酸序列顯示高互補性程度且對其他核酸序列顯示較低互補性程度的寡核苷酸。熟習此項技術者應認識到,可在較大範圍中選擇適用於本發明中之基因區域。
在以下情形時反股化合物係「可特異性雜交」:化合物與靶核酸之結合可干擾靶核酸之正常功能以調節功能及/或活性,且存在足夠互補性程度以避免反股化合物與非靶核酸序列在期望發生特異性結合之條件下(亦即,在活體內分析或治療性治療情形中之生理條件下,及在活體外分析情形中實施分析之條件下)發生非特異性結合。
本文所述寡核苷酸之雜交性質可藉由業內已知之一或多個活體外分析進行測定。舉例而言,可藉由使用熔融曲線分析測定靶天然反股分子及潛在藥物分子間之結合強度來獲得本文所述寡核苷酸之性質。
可使用量測分子間相互作用之強度之已確立方法中的任一者(例如,熔融曲線分析)來估計靶天然反股分子及潛在藥物分子(分子)間之
結合強度。
熔融曲線分析可測定對於天然反股分子/分子複合物自雙鏈快速轉變成單鏈形態時之溫度。此溫度已廣泛接受作為兩個分子間相互作用強度之可靠量度。
可使用實際天然反股RNA分子之cDNA拷貝或對應於分子結合位點之合成DNA或RNA核苷酸來實施熔融曲線分析。可使用含有所有必需試劑以實施此分析之多個套組(例如Applied Biosystems公司,MeltDoctor套組)。該等套組包含含有雙鏈DNA(dsDNA)結合染料(例如ABI HRM染料、SYBR Green、SYTO等)中之一者的適宜緩衝溶液。dsDNA染料之性質在於其幾乎不發射游離形式之螢光,但在與dsDNA結合時具有高螢光性。
為實施分析,以由特定製造商方案界定之濃度將cDNA或相應寡核苷酸與分子混合。將混合物加熱至95℃以離解所有預形成之dsDNA複合物,然後緩慢冷卻至室溫或由套組製造商界定之其他較低溫度以使DNA分子退火。然後將新形成複合物緩慢加熱至95℃,同時繼續收集關於反應中所產生螢光之量的數據。螢光強度與反應中存在之dsDNA量成反比。可使用與套組相容之實時PCR儀器(例如ABI's StepOne Plus實時PCR系統或lightTyper儀器,Roche Diagnostics,Lewes,UK)來收集數據。
藉由使用適當軟體(例如lightTyper(Roche)或SDS Dissociation Curve,ABI)繪製螢光相對於溫度之負導數(-d(螢光)/dT),y軸)與溫度(x軸)的圖線來構建熔融峰。分析數據以確定自dsDNA複合物快速轉變成單鏈分子時之溫度。此溫度稱為Tm且與兩個分子間之相互作用強度成正比。通常,Tm高於40℃。
實例2中所用之所有反股寡核苷酸皆如實例1中所述進行設計。指示製造商(IDT公司,Coralville,IA)來製造所設計之硫代磷酸酯鍵寡核苷酸並提供表1中所示之所設計硫代磷酸酯類似物。核苷酸間之星形符號表示存在硫代磷酸酯鍵。實例2中之實驗所需的寡核苷酸可使用任一適當技術狀態之方法來合成,例如IDT所用之方法:在固體載體(例如5微米定孔玻璃珠(CPG))上使用亞磷醯胺單體(常見核苷酸,其所有活性基團皆經保護基團保護,例如糖上之三苯甲基、A及C上之苯甲醯基及G上之N-2-異丁醯基)。保護基團在寡核苷酸合成期間可防止發生不期望之反應。在合成過程結束時去除保護基團。經由3'碳使初始核苷酸連接至固體載體且在3'至5'方向上進行合成。在以下4步中向生長之寡核苷酸鏈中添加新鹼基:1)使用三氯乙酸自固定核苷酸之5'氧處去除保護基團;2)使用四唑使經固定核苷酸與序列中之下一個核苷酸偶合至一起;經由四唑基亞磷醯胺中間體使反應繼續進行;3)洗滌除去未反應之游離核苷酸及反應副產物且將未反應之固定寡核苷酸封端以防止其參與下一輪合成;藉由使用乙酸酐及N-甲基咪唑對游離5'羥基實施乙醯化來達成封端;4)為穩定核苷酸間之鍵,使用碘及水(若欲產生磷酸二酯鍵)、或Beaucage試劑(3H-1,2-苯并二硫醇-3-酮-1,1-二氧化物)(若期望硫代磷酸酯鍵)來氧化磷。藉由交替使用兩種氧化劑,可構建嵌合主鏈。對於序列中之每一核苷酸而言,皆重複上述4步循環。合成完整序列時,在高溫下使用氫氧化銨自固體載體解離寡核苷酸並實施去保護。藉由去鹽來洗滌除去保護基團且將剩餘寡核苷酸凍乾。
為實施實例2中所設計之實驗,在37℃及5% CO2下於生長培養基(MEM/EBSS(Hyclone目錄編號:SH30024,或Mediatech目錄編號:MT-10-010-CV)+10% FBS(Mediatech目錄編號:MT35-011-CV)+青黴素(penicillin)/鏈黴素(streptomycin)(Mediatech目錄編號:MT30-002-
CI))中生長來自ATCC之HepG2細胞(目錄編號:HB-8065)。在實驗前一天,以0.5×104/ml之密度將細胞再次平鋪於6孔板中並在37℃及5% CO2下培育過夜。在實驗當天,將6孔板中之培養基更換為新鮮生長培養基。
將由製造商以凍乾形式運送之寡核苷酸在不含RNAse/DNAse之去離子水中稀釋至濃度為20μM。將2μl此溶液與400μl OptiMEM培養基(Gibco目錄編號:31985-070)及4μl Lipofectamine 2000(Invitrogen目錄編號:11668019)在室溫下一起培育20min,然後逐滴施加至6孔板中具有HepG2細胞之一個孔中。使用包含2μl水代替寡核苷酸溶液之相似混合物作為模擬轉染對照。在37℃及5% CO2下培育3-18h之後,將培養基更換為新鮮生長培養基。添加反股寡核苷酸48h後,去除培養基,且使用來自Promega之SV Total RNA分離系統(目錄編號:Z3105)或來自Qiagen之RNeasy Total RNA分離套組(目錄編號:74181)根據製造商說明書自細胞提取RNA。將600ng提取之RNA添加至使用來自Thermo Scientific之Verso cDNA套組(目錄編號:AB1453B)或高容量cDNA逆轉錄套組(目錄編號:4368813)實施的逆轉錄反應中,如製造商方案中所述。使用來自此逆轉錄反應之cDNA藉由實時PCR使用ABI Taqman Gene Expression Mix(目錄編號:4369510)及由ABI設計之引物/探針(Applied Biosystems Taqman Gene Expression Assay:Hs01088574_m1(PAR4),Applied Biosystems公司,Foster City CA)來監測基因表現。使用StepOne Plus實時PCR機器(Applied Biosystems)來實施下列PCR循環:在50℃下保持2min,在95℃下保持10min,40個循環之(在95℃下保持15秒,在60℃下保持1min)。基於經處理及模擬轉染試樣間18S標準化dCt值之差值來計算使用反股寡核苷酸處理後基因表現的變化倍數。
結果:實時PCR結果顯示,在使用設計為PAR4反股
jortybo.aApr07之寡聚物處理48h之後,HepG2細胞中之PAR4 mRNA之含量顯著增加(圖1)。
在37℃及5% CO2下於生長培養基(F-12K培養基(ATCC 30-2004)+10% FBS(Mediatech目錄編號:35-011-CV)+青黴素/鏈黴素(Mediatech目錄編號:MT30-002-CI))中生長來自ATCC之A549細胞(目錄編號:CCL-185)。在實驗前一天,以1.5×105/ml之密度將細胞再次平鋪於6孔板中並在37℃及5% CO2下培育。在實驗當天,將6孔板中之培養基更換為新鮮生長培養基。將所有反股寡核苷酸稀釋至濃度為20μM。將2μl此溶液與400μl Opti-MEM培養基(Gibco目錄編號:31985-070)及4μl Lipofectamine 2000(Invitrogen目錄編號:11668019)在室溫下一起培育20min,且施加至6孔板中具有A549細胞之每一孔中。使用包含2μl水代替寡核苷酸溶液之相似混合物作為模擬轉染對照。在37℃及5% CO2下培育3-18h之後,將培養基更換為新鮮生長培養基。添加反股寡核苷酸48h後,去除培養基,且使用來自Promega之SV Total RNA分離系統(目錄編號:Z3105)或來自Qiagen之RNeasy Total RNA分離套組(目錄編號:74181)根據製造商說明書自細胞提取RNA。將600ng RNA添加至使用來自Thermo Scientific之Verso cDNA套組(目錄編號:AB1453B)或高容量cDNA逆轉錄套組(目錄編號:4368813)實施的逆轉錄反應中,如製造商方案中所述。使用來自此逆轉錄反應之cDNA藉由實時PCR使用ABI Taqman Gene Expression Mix(目錄編號:4369510)及由ABI設計之引物/探針(Applied Biosystems Taqman Gene Expression Assay:Hs01088574_m1,Applied Biosystems公司,Foster City CA)來監測基因表現。使用Mx4000熱循環儀(Stratagene)或StepOne Plus實時PCR機器(Applied Biosystems)來實施下列PCR循環:在50℃下保持2min,在95℃下保持10min,40個
循環之(在95℃下保持15秒,在60℃下保持1min)。基於經處理及模擬轉染試樣間18S標準化dCt值之差值來計算使用反股寡核苷酸處理後基因表現的變化倍數。
結果:實時PCR結果顯示,在使用設計為PAR4反股jortybo.aApr07之寡CUR-1566處理後48h時,A459細胞中之PAR4 mRNA含量顯著增加。
在37℃及5% CO2下於生長培養基(MEM/EBSS(Hyclone目錄編號:SH30024,或Mediatech目錄編號:MT-10-010-CV)+10% FBS(Mediatech目錄編號:MT35-011-CV)+青黴素/鏈黴素(Mediatech目錄編號:MT30-002-CI))中生長來自ATCC之Hek293細胞(目錄編號:HB-1573)。在實驗前一天,以1.5×105/ml之密度將細胞再次平鋪於6孔板中並在37℃及5% CO2下培育。在實驗當天,將6孔板中之培養基更換為新鮮生長培養基。將所有反股寡核苷酸稀釋至濃度為20μM。將2μl此溶液與400μl Opti-MEM培養基(Gibco目錄編號:31985-070)及4μl Lipofectamine 2000(Invitrogen目錄編號:11668019)在室溫下一起培育20min,且施加至6孔板中具有Hek293細胞之每一孔中。使用包含2μl水代替寡核苷酸溶液之相似混合物作為模擬轉染對照。在37℃及5% CO2下培育3-18h之後,將培養基更換為新鮮生長培養基。添加反股寡核苷酸48h後,去除培養基,且使用來自Promega之SV Total RNA分離系統(目錄編號:Z3105)或來自Qiagen之RNeasy Total RNA分離套組(目錄編號:74181)根據製造商說明書自細胞提取RNA。將600ngRNA添加至使用來自Thermo Scientific之Verso cDNA套組(目錄編號:AB1453B)或高容量cDNA逆轉錄套組(目錄編號:4368813)實施的逆轉錄反應中,如製造商方案中所述。使用來自此逆轉錄反應之cDNA藉由實時PCR使用ABI Taqman Gene Expression Mix
(目錄編號:4369510)及由ABI設計之引物/探針(Applied Biosystems Taqman Gene Expression Assay:Hs01088574_m1,Applied Biosystems公司,Foster City CA)來監測基因表現。使用Mx4000熱循環儀(Stratagene)或StepOne Plus實時PCR機器(Applied Biosystems)來實施下列PCR循環:在50℃下保持2min,在95℃下保持10min,40個循環之(在95℃下保持15秒,在60℃下保持1min)。基於經處理及模擬轉染試樣間18S標準化dCt值之差值來計算使用反股寡核苷酸處理後基因表現的變化倍數。
結果:圖3顯示與對照相比,在使用利用Lipofectamine 2000引入之CUR-1566處理後48小時時HEK293細胞中之細胞凋亡有所增加。
在37℃及5% CO2下於生長培養基(角質形成細胞生長培養基,Lifeline目錄編號:LM0004+Lifeline生長因子1030)生長初級角質形成細胞(來自Lifeline Technologies)。在實驗前一天,以約5x10^4/ml(或90%鋪滿之約1/3稀釋度)將細胞再次平鋪於24孔膠原塗覆板(Beckton Dickinson BioCoat板,目錄編號:35 6408)中,並在37℃及5% CO2下培育過夜。在實驗當天,將24孔板中之培養基更換為1ml新鮮生長培養基。將由製造商以凍乾形式運送之寡核苷酸在不含RNAse/DNAse之去離子水中稀釋至濃度為20μM。將2μl此溶液與400μl OptiMEM培養基(Gibco目錄編號:31985-070)及4μl TransIT®-LT1轉染試劑(Mirus目錄編號:MIR 2300)在室溫下一起培育20min,然後逐滴施加至6孔板中具有HepG2細胞之一個孔中。使用包含2μl水代替寡核苷酸溶液之相似混合物作為模擬轉染對照。投藥後,將板在37℃、5% CO2下培育過夜。添加反股寡核苷酸後24h時,使用新鮮生長培養基代替培養基且如上所述重複投藥。第二次投藥24h時,使用來自Promega之SV Total RNA分離系統(目錄編號:Z3105)根據製造商說
明書自細胞提取RNA。將總共600ng RNA添加至逆轉錄反應中,該逆轉錄反應係使用來自Applied Biosystems之高容量cDNA套組(目錄編號:4368813)如製造商方案中所述來實施。使用來自此逆轉錄反應之cDNA藉由實時PCR使用ABI Taqman Gene Expression Mix(目錄編號:4369510)及由ABI設計之引物/探針(Hs01088574_m1)來監測基因表現。使用StepOne Plus實時PCR機器(Applied Biosystems)來實施下列PCR循環:在50℃下保持2min,在95℃下保持10min,40個循環之(在95℃下保持15秒,在60℃下保持1min)。基於經處理及模擬轉染試樣間18S標準化dCt值之差值來計算使用反股寡核苷酸處理後基因表現的變化倍數。
結果:圖4顯示與對照相比,在使用利用Lipofectamine 2000引入之CUR-1566處理後48小時時角質形成細胞中之細胞凋亡有所增加(圖4)。
使用HT Titer TACS分析套組根據製造商方案(Trevigen目錄編號:4822-96-K)檢測細胞中之細胞凋亡程度。簡言之,對寡核苷酸轉染48小時後之細胞實施胰蛋白酶化,計數並以100,000細胞/孔之密度再次平鋪於96孔板中。然後將96孔板在37℃、5% CO2下培育過夜。次日早晨,去除培養基且將細胞固定於使用PBS及100%甲醇(Sigma-M1775-1GA)沖洗之3.7%緩衝甲醛溶液(Sigma-252549)中,並在+4℃下儲存於80%乙醇(Sigma-493511)中。
為標記DNA斷裂,去除乙醇,且使用PBS洗滌細胞並與蛋白酶K溶液在室溫下一起培育15分鐘,在水及PBS中沖洗,然後與TACS核酸酶溶液在37℃下一起培育10分鐘。培育後,使用PBS沖洗細胞,且在室溫下經5分鐘添加過氧化氫溶液(Sigma-MKBD1394)。然後將細胞與1x TdT標記在室溫下一起再培育5分鐘。去除緩衝液且隨後將細胞
與標記反應混合物在37℃下一起培育一小時,且然後經5分鐘添加1x TdT終止緩衝液。標記反應停止後,使用PBS洗滌細胞,與Strep-HRP溶液在室溫下一起培育10分鐘,使用PBS/Tween洗滌且與TACS蘭寶石在暗處一起培育30分鐘。藉由添加0.2N HCl(Fluka-343102)來停止反應,且在450nm下於板讀數儀中讀取吸光度。
1. 使用CUR-1565、CUR-1566及CUR-1568在20nM下使用LipofectamineTM 2000轉染試劑(Invitrogen)來轉染Hep G2細胞(ATCC目錄編號:HB-8065)。亦使用20nM CUR-1505(無活性寡核苷酸)且使用LipofectamineTM 2000及水(模擬轉染)來轉染細胞子組。
結果:與對照相比,在使用利用Lipofectamine 2000引入之硫代磷酸酯寡聚物處理後48小時時,HepG2細胞中之細胞凋亡顯著增加(圖5)。
2. 使用CUR-1565、CUR-1566及CUR-1568在20nM下使用LipofectamineTM 2000轉染試劑(Invitrogen)來轉染來自ATCC之MCF-7細胞(目錄編號:HTB-22)。
結果:與對照相比,在使用利用Lipofectamine 2000引入之CUR-1566處理後48小時時,MCF-7細胞中之細胞凋亡顯著增加(圖6)。
儘管已根據一或多個實施方案闡釋及闡述了本發明,但熟習此項技術者在閱讀並理解本說明書及附圖後可作出等效改變及修改。此外,儘管可能只根據多種實施方案中之一者揭示了本發明之特定特徵,但該特徵可與其他實施方案之一或多個其他特徵組合,此對於任何給定或特定之應用而言可能係合乎要求且有利的。
本揭示內容之摘要使得讀者可快速地確定技術揭示內容之性質。提交本摘要係基於以下理解:其並非用於解釋或限制下列申請專利範圍之範圍或含義。
1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they
control. Nat Med. 2004; 10:789-799。
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70。
3. Evan GI, Wyllie AH, Gilbert CS等人,Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992; 69:119-128。
4. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis. Oncogene. 1991; 6:1915-1922。
5. Klefstrom J, Västrik I, Saksela E, Valle J, Eilers M, Alitalo K. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J. 1994; 13:5442-5450。
6. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene. 1998; 17:339-346。
7. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005; 258:479-517。
8. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004; 432:307-315。
9. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003; 22:7414-7430。
10. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005; 5:876-885。
11. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev. 2005; 57:187-215。
12. Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol. 2006; 3:388-398。
13. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005; 106:408-418。
14. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (Review). Int J Oncol. 1998; 12:141-152。
15. Filomenko R, Prévotat L, Rébé C等人,Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene. 2006; 25:7635-7645。
16. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001; 20:1063-1075。
17. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001; 61:1645-1651。
18. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 1999; 19; 274:7987-7992。
19. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 2003; 8:413-450。
20. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol
induces caspase-10-dependent apoptosis. J Biol Chem. 2004; 279:51057-51067。
21. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel-or etoposide-treated HL-60 cells. Cancer Res. 1998; 58:4561-4566。
22. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003; 22:9030-9040。
23. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun. 2005; 331:851-858。
24. Ashkenazi A, Pai RC, Fong S等人,Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104:155-162。
25. Lee JM, Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A. 1993; 90:5742-5746。
26. Bunz F, Hwang PM, Torrance C等人,Disruption of p53 in human cancer cells alters the response to therapeutic agents. J Clin Invest. 1999; 104:263-269。
27. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008; 26:3621-3630。
28. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2:420-430。
29. Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer. 2002;
97:458-465。
30. Mühlethaler-Mottet A, Bourloud KB, Auderset K, Joseph JM, Gross N. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Oncogene. 2004; 23:5415-5425。
31. Ravi R, Jain AJ, Schulick RD等人,Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 2004; 64:9105-9114。
32. Jansen B, Schlagbauer-Wadl H, Brown BD等人,Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med. 1998; 4:232-234。
33. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002; 12:193-213。
34. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest. 2005; 115:2648-2655。
35. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008; 7:1001-1012。
<110> 美商歐科可娜有限責任公司
<120> 藉由抑制PAR4天然反股轉錄本治療PAR4相關疾病
<130> PAR4
<150> US61/334933
<151> 2010-05-14
<160> 9
<170> PatentIn version 3.5
<210> 1
<211> 1967
<212> DNA
<213> 智人
<400> 1
<210> 2
<211> 354
<212> DNA
<213> 智人
<400> 2
<210> 3
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> 反股寡核苷酸
<400> 3
<210> 4
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> 反股寡核苷酸
<400> 4
<210> 5
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> 反股寡核苷酸
<400> 5
<210> 6
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> 反股寡核苷酸
<400> 6
<210> 7
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> 反股寡核苷酸
<400> 7
<210> 8
<211> 19
<212> DNA
<213> 人工序列
<220>
<223> 反股寡核苷酸
<400> 8
<210> 9
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 反股寡核苷酸
<400> 9
Claims (14)
- 一種長度為12至26個核苷酸的反股寡核苷酸,其中該反股寡核苷酸對PAR4基因之天然反股多核苷酸具有特異性且與其特異性雜交,其中該天然反股多核苷酸實質上由SEQ ID NO:2所組成。
- 一種長度為14至24個核苷酸的反股寡核苷酸,其中該反股寡核苷酸特異性靶向且特異性雜交該PAR4多核苷酸之天然反股多核苷酸的區域,其中該天然反股多核苷酸包含SEQ ID NO:2。
- 如請求項2之反股寡核苷酸,其中在體內(in vivo)或活體外(in vitro)該PAR4之功能及/或表現相對於對照有所增強。
- 如請求項2之反股寡核苷酸,其中該反股寡核苷酸靶向天然反股多核苷酸,該天然反股多核苷酸反股於PAR4 RNA多核苷酸之編碼核酸序列。
- 如請求項2之反股寡核苷酸,其中該反股寡核苷酸靶向天然反股多核苷酸,該天然反股多核苷酸具有與PAR4多核苷酸重疊之序列。
- 如請求項2之反股寡核苷酸,其中該反股寡核苷酸包括一或多個選自以下之修飾:至少一個經修飾糖部分、至少一個經修飾核苷間鍵聯、至少一個經修飾核苷酸及其組合。
- 如請求項6之反股寡核苷酸,其中該一或多個修飾包括至少一個選自以下之經修飾糖部分:經2'-O-甲氧基乙基修飾之糖部分、經2'-甲氧基修飾之糖部分、經2'-O-烷基修飾之糖部分、雙環糖部分及其組合。
- 如請求項6之反股寡核苷酸,其中該一或多個修飾包括至少一個選自以下之經修飾核苷間鍵聯:硫代磷酸酯、膦酸烷基酯、二硫代磷酸酯、硫代膦酸烷基酯、胺基磷酸酯、胺基甲酸酯、碳 酸酯、磷酸三酯、胺基乙酸酯、羧甲基酯及其組合。
- 如請求項6之反股寡核苷酸,其中該一或多個修飾包括至少一個選自以下之經修飾核苷酸:肽核酸(PNA)、鎖核酸(LNA)、阿糖核酸(FANA)、其類似物、衍生物及組合。
- 如請求項1之反股寡核苷酸,其中該寡核苷酸包括至少一個闡述為SEQ ID NO:3至9之寡核苷酸序列。
- 一種長度為19至30個核苷酸的短干擾RNA(siRNA)寡核苷酸,其用於上調哺乳動物體內(in vivo)細胞或組織中PAR4基因之功能及/或表現,其中該siRNA寡核苷酸對PAR4多核苷酸之天然反股多核苷酸具有特異性且與其特異性雜交,其中該天然反股多核苷酸實質上由SEQ ID NO:2所組成,且其中該siRNA寡核苷酸與鄰近於該PAR4多核苷酸之非重疊RNA之至少約19個連續核酸具有至少90%的序列一致性。
- 一種長度為約12至24個核苷酸的反股寡核苷酸,其中該反股寡核苷酸對PAR4多核苷酸之天然反股具有特異性且與其特異性雜交,其中該天然反股實質上由SEQ ID NO:2所組成,且其中該反股寡核苷酸與至少一個闡述為SEQ ID NO:1之核酸序列或自PAR4多核苷酸轉錄之RNA具有至少90%的序列一致性。
- 一種長度為12至24個核苷酸的反股寡核苷酸,其中該反股寡核苷酸特異性結合至至少一種PAR4多核苷酸之天然反股序列並上調該至少一種PAR4多核苷酸之表現,其中該天然反股序列實質上由SEQ ID NO:2所組成。
- 一種醫藥組合物,其包含如請求項1至13中任一項之寡核苷酸及醫藥上可接受賦形劑。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33493310P | 2010-05-14 | 2010-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201618793A TW201618793A (zh) | 2016-06-01 |
TWI586356B true TWI586356B (zh) | 2017-06-11 |
Family
ID=44915016
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW100116946A TWI531370B (zh) | 2010-05-14 | 2011-05-13 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
TW105105551A TWI586356B (zh) | 2010-05-14 | 2011-05-13 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW100116946A TWI531370B (zh) | 2010-05-14 | 2011-05-13 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
Country Status (13)
Country | Link |
---|---|
US (3) | US8980857B2 (zh) |
EP (1) | EP2569432B1 (zh) |
JP (1) | JP5982362B2 (zh) |
KR (1) | KR101844091B1 (zh) |
CN (1) | CN102985543B (zh) |
AR (1) | AR081398A1 (zh) |
CA (1) | CA2798401C (zh) |
DK (1) | DK2569432T3 (zh) |
ES (1) | ES2671901T3 (zh) |
NO (1) | NO2569432T3 (zh) |
SA (1) | SA111320451B1 (zh) |
TW (2) | TWI531370B (zh) |
WO (1) | WO2011143640A2 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
CN104583398A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节基因表达的组合物和方法 |
DK2850186T3 (en) | 2012-05-16 | 2019-04-08 | Translate Bio Ma Inc | COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION |
JP2015518710A (ja) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
KR20160074368A (ko) | 2012-05-16 | 2016-06-28 | 라나 테라퓨틱스, 인크. | Utrn 발현을 조절하기 위한 조성물 및 방법 |
WO2013173598A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating atp2a2 expression |
WO2013173608A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating mecp2 expression |
WO2016004955A1 (en) | 2014-07-09 | 2016-01-14 | Haldor Topsøe A/S | Process for producing hydrogen |
WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
EP3271460A4 (en) | 2015-03-17 | 2019-03-13 | The General Hospital Corporation | INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1) |
CN110290794A (zh) | 2016-11-01 | 2019-09-27 | 纽约州州立大学研究基金会 | 5-卤代尿嘧啶修饰的微rna及其在癌症治疗中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040203024A1 (en) * | 1996-06-06 | 2004-10-14 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
Family Cites Families (390)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
JP2828642B2 (ja) | 1987-06-24 | 1998-11-25 | ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン | ヌクレオシド誘導体 |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
DE3855864T2 (de) | 1987-11-30 | 1997-09-25 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
US5288512A (en) | 1987-12-15 | 1994-02-22 | The Procter & Gamble Company | Reduced calorie fats made from triglycerides containing medium and long chain fatty acids |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
NL8800756A (nl) | 1988-03-25 | 1989-10-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Genetisch gemanipuleerde plantecellen en planten, alsmede daarvoor bruikbaar recombinant dna. |
JPH03503894A (ja) | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | オリゴヌクレオチド n‐アルキルホスホラミデート |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
US6203976B1 (en) | 1989-07-18 | 2001-03-20 | Osi Pharmaceuticals, Inc. | Methods of preparing compositions comprising chemicals capable of transcriptional modulation |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
EP0497875B1 (en) | 1989-10-24 | 2000-03-22 | Isis Pharmaceuticals, Inc. | 2' modified oligonucleotides |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5852188A (en) | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
WO1991013080A1 (en) | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
US6034233A (en) | 1990-05-04 | 2000-03-07 | Isis Pharmaceuticals Inc. | 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome |
DK0455905T3 (da) | 1990-05-11 | 1998-12-07 | Microprobe Corp | Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5614617A (en) | 1990-07-27 | 1997-03-25 | Isis Pharmaceuticals, Inc. | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
MY107332A (en) | 1990-08-03 | 1995-11-30 | Sterling Drug Inc | Compounds and methods for inhibiting gene expression. |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
US5596086A (en) | 1990-09-20 | 1997-01-21 | Gilead Sciences, Inc. | Modified internucleoside linkages having one nitrogen and two carbon atoms |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
EP0556301B1 (en) | 1990-11-08 | 2001-01-10 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
DE69128037T2 (de) | 1990-11-13 | 1998-05-07 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
US6307040B1 (en) | 1992-03-05 | 2001-10-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US5605662A (en) | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
IL101600A (en) | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
JPH08501686A (ja) | 1992-09-25 | 1996-02-27 | ローン−プーラン・ロレ・ソシエテ・アノニム | 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター |
US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
AU674891B2 (en) | 1992-10-15 | 1997-01-16 | Toray Industries, Inc. | Process for producing major histocompatibility antigen class II protein and material having the same immobilized thereon |
US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
AU6449394A (en) | 1993-03-30 | 1994-10-24 | Sterling Winthrop Inc. | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
JPH08508491A (ja) | 1993-03-31 | 1996-09-10 | スターリング ウインスロップ インコーポレイティド | ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
AU6786594A (en) | 1993-05-11 | 1994-12-12 | University Of North Carolina At Chapel Hill, The | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
CA2177031A1 (en) | 1993-11-30 | 1995-06-08 | Moshe Szyf | Inhibition of dna methyltransferase |
US5908779A (en) | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
EP0733059B1 (en) | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
AU1925195A (en) | 1994-02-22 | 1995-09-04 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
FR2727867B1 (fr) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
GB9501465D0 (en) | 1995-01-25 | 1995-03-15 | King S College London | Nucleoside phosphorothioate derivatives,synthesis and use thereof |
DE19502912A1 (de) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
IT1276642B1 (it) | 1995-03-03 | 1997-11-03 | Consiglio Nazionale Ricerche | Trascritto antisenso presente in linfociti b ed oligodeossinucleotidi sintetici utili per inibirne l'azione |
US5543165A (en) | 1995-06-06 | 1996-08-06 | Hill; Julie B. | Process of making a soluble tea product with champagne-like properties |
US5739311A (en) | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
CZ243498A3 (cs) | 1996-02-14 | 1999-09-15 | Isis Pharmaceuticals, Inc. | Oligonukleotidy s mezerou a modifikovaným cukrem |
IL125839A0 (en) | 1996-03-14 | 1999-04-11 | Genentech Inc | Uses of gdnf and gdnf receptor |
AU2733697A (en) | 1996-04-17 | 1997-11-07 | Aronex Pharmaceuticals, Inc. | Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression |
US5786213A (en) | 1996-04-18 | 1998-07-28 | Board Of Regents, The University Of Texas System | Inhibition of endogenous gastrin expression for treatment of colorectal cancer |
US5756710A (en) | 1996-06-05 | 1998-05-26 | The Trustees Of Columbia University In City Of New York | Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
US7008776B1 (en) | 1996-12-06 | 2006-03-07 | Aventis Pharmaceuticals Inc. | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
US7235653B2 (en) | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6013786A (en) | 1997-08-22 | 2000-01-11 | Hybridon, Inc. | MDM2-specific antisense oligonucleotides |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
NZ503765A (en) | 1997-09-12 | 2002-04-26 | Exiqon As | Bi-cyclic and tri-cyclic nucleotide analogues |
US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US6034883A (en) | 1998-01-29 | 2000-03-07 | Tinney; Charles E. | Solid state director for beams |
US6175409B1 (en) | 1999-04-02 | 2001-01-16 | Symyx Technologies, Inc. | Flow-injection analysis and variable-flow light-scattering methods and apparatus for characterizing polymers |
US7321828B2 (en) | 1998-04-13 | 2008-01-22 | Isis Pharmaceuticals, Inc. | System of components for preparing oligonucleotides |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
US6221587B1 (en) | 1998-05-12 | 2001-04-24 | Isis Pharmceuticals, Inc. | Identification of molecular interaction sites in RNA for novel drug discovery |
US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
AU757724B2 (en) | 1998-05-26 | 2003-03-06 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
US6100090A (en) | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
US20030139359A1 (en) | 2001-12-04 | 2003-07-24 | Isis Pharmaceuticals Inc. | Antisense modulation of phospholipid scramblase 3 expression |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
WO2000027424A2 (en) | 1998-11-06 | 2000-05-18 | Alcon Laboratories, Inc. | Upregulation of endogenous prostaglandins to lower intraocular pressure |
US5985663A (en) | 1998-11-25 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of interleukin-15 expression |
ES2377749T3 (es) | 1999-01-27 | 2012-03-30 | Coda Therapeutics, Inc. | Formulaciones que comprenden nucleótidos antisentidos para conexinas |
BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
EP1163254B1 (en) | 1999-02-26 | 2008-01-30 | The University of British Columbia | Trpm-2 antisense therapy |
US20040137423A1 (en) | 1999-03-15 | 2004-07-15 | Hayden Michael R. | Compositions and methods for modulating HDL cholesterol and triglyceride levels |
DE1100895T1 (de) | 1999-03-15 | 2001-09-06 | Univ British Columbia | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
WO2000056916A2 (en) | 1999-03-18 | 2000-09-28 | Exiqon A/S | Detection of mutations in genes by specific lna primers |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
JP4768132B2 (ja) | 1999-03-24 | 2011-09-07 | エクシコン エ/エス | [2.2.1]ビシクロヌクレオシドの改良された製法 |
US6734291B2 (en) | 1999-03-24 | 2004-05-11 | Exiqon A/S | Synthesis of [2.2.1]bicyclo nucleosides |
MXPA01009727A (es) | 1999-03-26 | 2002-07-22 | Aventis Pharma Inc | Composiciones y metodos para afectar los niveles de colesterol asociado a lipoproteina de alta densidad (hdl) y a apolipoproteina a1, colesterol asociado a lipoproteina de muy baja densidad (vldl) y colesterol asociado a lipoproteina de baja densidad |
ES2300261T3 (es) | 1999-04-08 | 2008-06-16 | Novartis Vaccines And Diagnostics, Inc. | Potenciacion de la respuesta inmune para aplicaciones de vacunas y terapia genetica. |
US6977295B2 (en) | 1999-04-21 | 2005-12-20 | Invitrogen Corporation | Locked nucleic acid hybrids and methods of use |
CA2372085C (en) | 1999-05-04 | 2009-10-27 | Exiqon A/S | L-ribo-lna analogues |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
DE19925073C2 (de) | 1999-06-01 | 2001-07-19 | Stefan Weiss | Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
WO2001000669A2 (en) | 1999-06-25 | 2001-01-04 | Genset | A bap28 gene and protein |
US20040006031A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of HMG-CoA reductase expression |
US6147200A (en) | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
WO2001016311A1 (fr) | 1999-08-31 | 2001-03-08 | Hisamitsu Pharmaceutical Co., Inc. | DOMAINE DE DELETION 1p36 DE L'HOMOZYGOTISME HUMAIN |
EP1218411A4 (en) | 1999-09-20 | 2004-09-01 | Millennium Pharm Inc | SECRETED PROTEINS AND THEIR USES |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
US6986988B2 (en) | 1999-10-06 | 2006-01-17 | Quark Biotech, Inc. | Method for enrichment of natural antisense messenger RNA |
US6528262B1 (en) | 1999-10-06 | 2003-03-04 | Quark Biotech, Inc. | Method for enrichment of natural antisense messenger RNA |
AU2778801A (en) | 2000-01-07 | 2001-07-24 | Baylor University | Antisense compositions and methods |
WO2001051490A1 (en) | 2000-01-14 | 2001-07-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methanocarba cycloalkyl nucleoside analogues |
US6303374B1 (en) | 2000-01-18 | 2001-10-16 | Isis Pharmaceuticals Inc. | Antisense modulation of caspase 3 expression |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
JP2001247459A (ja) | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
US6936467B2 (en) | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
OA12240A (en) | 2000-03-27 | 2006-05-10 | Univ Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides. |
DE10019136A1 (de) * | 2000-04-18 | 2001-10-31 | Aventis Pharma Gmbh | Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung |
US7402434B2 (en) | 2000-05-08 | 2008-07-22 | Newman Stuart A | Splice choice antagonists as therapeutic agents |
EP1294754A1 (en) | 2000-06-29 | 2003-03-26 | Pharma Pacific Pty. Ltd. | Interferon-alpha induced gene |
JP2004505047A (ja) | 2000-07-28 | 2004-02-19 | キャンサー・リサーチ・テクノロジー・リミテッド | 複合治療による癌治療 |
WO2002018388A1 (fr) | 2000-08-29 | 2002-03-07 | Takeshi Imanishi | Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues |
ATE385505T1 (de) | 2000-09-02 | 2008-02-15 | Gruenenthal Gmbh | Antisense oligonukleotide gegen vr 1 |
US6444464B1 (en) | 2000-09-08 | 2002-09-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of E2F transcription factor 2 expression |
WO2002024717A1 (en) | 2000-09-20 | 2002-03-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of flip-c expression |
AU2002210295A1 (en) | 2000-10-13 | 2002-04-22 | Institut De Cardiologie De Montreal | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof |
US20030228618A1 (en) | 2000-11-24 | 2003-12-11 | Erez Levanon | Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same |
US20050222029A1 (en) | 2001-01-04 | 2005-10-06 | Myriad Genetics, Incorporated | Compositions and methods for treating diseases |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US20020147165A1 (en) | 2001-02-22 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of calreticulin expression |
AU2002234755A1 (en) | 2001-02-26 | 2002-09-12 | Pharma Pacific Pty Ltd | Interferon-alpha induced gene |
AUPR497101A0 (en) | 2001-05-14 | 2001-06-07 | Queensland University Of Technology | Polynucleotides and polypeptides linked to cancer and/or tumorigenesi |
US20050222066A1 (en) * | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
IL143379A (en) | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
US7053195B1 (en) | 2001-06-12 | 2006-05-30 | Syngenta Participatious Ag | Locked nucleic acid containing heteropolymers and related methods |
US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
CA2453183C (en) | 2001-07-12 | 2016-05-10 | University Of Massachusetts | In vivo production of small interfering rnas that mediate gene silencing |
US7153954B2 (en) | 2001-07-12 | 2006-12-26 | Santaris Pharma A/S | Method for preparation of LNA phosphoramidites |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7259150B2 (en) | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
AU2002334307A1 (en) | 2001-09-04 | 2003-03-18 | Exiqon A/S | Novel lna compositions and uses thereof |
US6936589B2 (en) | 2001-09-28 | 2005-08-30 | Albert T. Naito | Parenteral delivery systems |
US20040214766A1 (en) | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
JP4276945B2 (ja) | 2001-10-10 | 2009-06-10 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | α−D−ガラクトシダーゼ活性が低下したコーヒー植物 |
AR037699A1 (es) | 2001-12-04 | 2004-12-01 | Monsanto Technology Llc | Maiz transgenico con fenotipo mejorado |
US7125982B1 (en) | 2001-12-05 | 2006-10-24 | Frayne Consultants | Microbial production of nuclease resistant DNA, RNA, and oligo mixtures |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
CA2365811A1 (en) | 2001-12-21 | 2003-06-21 | Institut De Cardiologie | A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury |
KR20030056538A (ko) | 2001-12-28 | 2003-07-04 | 주식회사 웰진 | 리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발 |
US20030191075A1 (en) | 2002-02-22 | 2003-10-09 | Cook Phillip Dan | Method of using modified oligonucleotides for hepatic delivery |
AU2003212729A1 (en) | 2002-02-25 | 2003-09-09 | Gunnar Norstedt | Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof |
WO2003072741A2 (en) | 2002-02-26 | 2003-09-04 | Southern Illinois University | Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
AU2003225701A1 (en) | 2002-03-08 | 2003-09-22 | Glen Research Corporation | Fluorescent nitrogenous base and nucleosides incorporating same |
GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
US7169916B2 (en) | 2002-04-01 | 2007-01-30 | Isis Pharmaceuticals, Inc. | Chloral-free DCA in oligonucleotide synthesis |
US20050215504A1 (en) | 2002-04-02 | 2005-09-29 | Bennett C F | Antisense modulation of sterol regulatory element-binding protein-1 expression |
DK2264172T3 (da) | 2002-04-05 | 2017-11-27 | Roche Innovation Ct Copenhagen As | Oligomerforbindelser til modulering af HIF-1á-ekspression |
US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
US6808906B2 (en) | 2002-05-08 | 2004-10-26 | Rigel Pharmaceuticals, Inc. | Directionally cloned random cDNA expression vector libraries, compositions and methods of use |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US20040033480A1 (en) | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
WO2004024079A2 (en) | 2002-09-10 | 2004-03-25 | The Samuel Roberts Noble Foundation, Inc. | Methods and compositions for production of flavonoid and isoflavonoid nutraceuticals |
US20060211640A1 (en) | 2002-09-25 | 2006-09-21 | Kane Christopher D | Antisense modulation of farnesoid X receptor expression |
EP1549767A4 (en) | 2002-09-26 | 2006-06-07 | Amgen Inc | MODULATION OF FORKHEAD BOX O1A GENE EXPRESSION |
KR20050083855A (ko) | 2002-11-01 | 2005-08-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | HIF-1 알파의 siRNA 억제를 위한 조성물 및 방법 |
GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
AU2003261405A1 (en) | 2002-11-01 | 2004-06-07 | University Of Massachusetts | Regulation of transcription elongation factors |
AU2003290596B2 (en) | 2002-11-05 | 2011-05-12 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US20060009410A1 (en) | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
CA2994089A1 (en) | 2002-11-18 | 2004-06-03 | Roche Innovation Center Copenhagen A/S | Antisense gapmer oligonucleotides |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US7339051B2 (en) | 2003-04-28 | 2008-03-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
WO2004108081A2 (en) | 2003-06-02 | 2004-12-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide synthesis with alternative solvents |
WO2005002507A2 (en) | 2003-06-03 | 2005-01-13 | Isis Pharmaceuticals, Inc. | Modulation of survivin expression |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
BRPI0413930A (pt) | 2003-09-18 | 2006-10-24 | Isis Pharmaceuticals Inc | composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste |
US8258105B2 (en) | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
WO2005045034A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) |
DE602004027163D1 (de) | 2003-12-23 | 2010-06-24 | Santaris Pharma As | Oligomere verbindungen zur modulation von bcl-2 |
NZ548447A (en) | 2004-01-12 | 2010-04-30 | Univ Pennsylvania | Up-regulation of bone morphogenetic protein (BMP) gene expression in bone cells by electromagnetic signals |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
GB0403041D0 (en) | 2004-02-11 | 2004-03-17 | Milner Anne J | Induction of apoptosis |
EP1566202A1 (en) | 2004-02-23 | 2005-08-24 | Sahltech I Göteborg AB | Use of resistin antagonists in the treatment of rheumatoid arthritis |
US7402574B2 (en) | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
WO2006085987A2 (en) | 2004-07-09 | 2006-08-17 | University Of Iowa Research Foundation | Rna interference in respiratory epitheial cells |
US7427675B2 (en) | 2004-08-23 | 2008-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
WO2006050734A2 (en) | 2004-11-09 | 2006-05-18 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a expression |
US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
AU2006261732B2 (en) | 2005-06-27 | 2011-09-15 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of HIF-1 and theraputic uses thereof |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
US8501703B2 (en) | 2005-08-30 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
EP1941059A4 (en) | 2005-10-28 | 2010-11-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE HUNTINGTIN GENE |
CA2626584A1 (en) | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
AU2006336624B2 (en) | 2005-11-17 | 2010-11-25 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
CA2630602A1 (en) * | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
US20070248590A1 (en) | 2005-12-02 | 2007-10-25 | Sirtris Pharmaceuticals, Inc. | Modulators of CDC2-like kinases (CLKS) and methods of use thereof |
US20070231816A1 (en) | 2005-12-09 | 2007-10-04 | Baylor Research Institute | Module-Level Analysis of Peripheral Blood Leukocyte Transcriptional Profiles |
CN100356377C (zh) | 2005-12-20 | 2007-12-19 | 无锡永中科技有限公司 | 文档显示方法 |
US20070213274A1 (en) | 2005-12-20 | 2007-09-13 | Oy Jurilab Ltd | Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C) |
US8288354B2 (en) | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
EP1984381B1 (en) | 2006-01-27 | 2010-09-29 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
CN101448849B (zh) | 2006-03-31 | 2013-08-21 | 阿尔尼拉姆医药品有限公司 | 抑制Eg5基因表达的组合物和方法 |
JP5825754B2 (ja) | 2006-05-05 | 2015-12-02 | アイシス ファーマシューティカルズ, インコーポレーテッド | Apobの発現を調節するための化合物および方法 |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
NZ572666A (en) | 2006-05-11 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene |
ES2389737T3 (es) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en 5' |
EP1867338A1 (en) | 2006-05-30 | 2007-12-19 | Université Libre De Bruxelles | Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases |
WO2008010800A1 (en) | 2006-07-19 | 2008-01-24 | President And Fellows Of Harvard College | Par-4 related methods and compositions |
WO2008066672A2 (en) | 2006-11-06 | 2008-06-05 | Beth Israel Deaconess Medical Center | Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases |
WO2008057556A2 (en) | 2006-11-06 | 2008-05-15 | Beth Israel Deaconess Medical Center | Identification and use of small molecules to modulate ese-1 transcription factor function and to treat ese-1 transcription factor associated diseases |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
CA2675946A1 (en) | 2007-01-19 | 2008-07-24 | Lionel Navarro | Methods and compositions for modulating the sirna and rna-directed-dna methylation pathways |
CA2686933A1 (en) | 2007-04-06 | 2008-10-16 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
US20090022729A1 (en) | 2007-04-13 | 2009-01-22 | Nigel Mackman | Methods and compositions for treating cardiac dysfunctions |
US20080293142A1 (en) | 2007-04-19 | 2008-11-27 | The Board Of Regents For Oklahoma State University | Multiple shRNA Expression Vectors and Methods of Construction |
EP2060583A1 (en) * | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
WO2010002984A1 (en) | 2008-07-01 | 2010-01-07 | Monsanto Technology, Llc | Recombinant dna constructs and methods for modulating expression of a target gene |
EP2352830B1 (en) | 2008-10-03 | 2019-01-16 | CuRNA, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
US8606289B2 (en) | 2008-11-10 | 2013-12-10 | Qualcomm Incorporated | Power headroom-sensitive scheduling |
EP2358382A2 (en) | 2008-11-22 | 2011-08-24 | The University of Bristol | NOVEL USES OF VEGFxxxB |
US9209196B2 (en) | 2011-11-30 | 2015-12-08 | Sharp Kabushiki Kaisha | Memory circuit, method of driving the same, nonvolatile storage device using the same, and liquid crystal display device |
-
2011
- 2011-05-13 TW TW100116946A patent/TWI531370B/zh active
- 2011-05-13 TW TW105105551A patent/TWI586356B/zh not_active IP Right Cessation
- 2011-05-14 NO NO11781397A patent/NO2569432T3/no unknown
- 2011-05-14 JP JP2013510358A patent/JP5982362B2/ja active Active
- 2011-05-14 DK DK11781397.2T patent/DK2569432T3/en active
- 2011-05-14 CN CN201180028004.5A patent/CN102985543B/zh active Active
- 2011-05-14 SA SA111320451A patent/SA111320451B1/ar unknown
- 2011-05-14 WO PCT/US2011/036557 patent/WO2011143640A2/en active Application Filing
- 2011-05-14 US US13/697,875 patent/US8980857B2/en active Active
- 2011-05-14 CA CA2798401A patent/CA2798401C/en active Active
- 2011-05-14 ES ES11781397.2T patent/ES2671901T3/es active Active
- 2011-05-14 KR KR1020127031568A patent/KR101844091B1/ko active IP Right Grant
- 2011-05-14 EP EP11781397.2A patent/EP2569432B1/en active Active
- 2011-05-16 AR ARP110101675A patent/AR081398A1/es unknown
-
2015
- 2015-02-10 US US14/618,162 patent/US9745584B2/en active Active
-
2017
- 2017-07-25 US US15/659,122 patent/US10100315B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040203024A1 (en) * | 1996-06-06 | 2004-10-14 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
Non-Patent Citations (1)
Title |
---|
年09月,Azmi AS. et al. " Critical role of prostateapoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. "Mol Cancer Ther. 2008, 7(9):2884-93. * |
Also Published As
Publication number | Publication date |
---|---|
KR101844091B1 (ko) | 2018-03-30 |
RU2012146816A (ru) | 2014-06-20 |
US20150152426A1 (en) | 2015-06-04 |
ES2671901T3 (es) | 2018-06-11 |
AR081398A1 (es) | 2012-08-29 |
EP2569432A2 (en) | 2013-03-20 |
EP2569432A4 (en) | 2014-10-01 |
CA2798401A1 (en) | 2011-11-17 |
US20170327828A1 (en) | 2017-11-16 |
DK2569432T3 (en) | 2018-02-05 |
CA2798401C (en) | 2018-08-21 |
CN102985543A (zh) | 2013-03-20 |
TWI531370B (zh) | 2016-05-01 |
WO2011143640A3 (en) | 2012-03-01 |
EP2569432B1 (en) | 2017-11-01 |
TW201618793A (zh) | 2016-06-01 |
JP5982362B2 (ja) | 2016-08-31 |
US9745584B2 (en) | 2017-08-29 |
NO2569432T3 (zh) | 2018-03-31 |
US10100315B2 (en) | 2018-10-16 |
CN102985543B (zh) | 2017-09-08 |
KR20130062943A (ko) | 2013-06-13 |
TW201143781A (en) | 2011-12-16 |
US8980857B2 (en) | 2015-03-17 |
SA111320451B1 (ar) | 2015-01-21 |
US20130065947A1 (en) | 2013-03-14 |
JP2013533850A (ja) | 2013-08-29 |
WO2011143640A2 (en) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6738841B2 (ja) | 脳由来神経栄養因子(bdnf)に対する天然アンチセンス転写物の阻害によるbdnf関連の疾患の処置 | |
TWI586356B (zh) | 藉由抑制par4天然反股轉錄本治療par4相關疾病 | |
TWI614016B (zh) | 以針對無調同源物1(atoh1)之天然反義轉錄本之抑制作用治療atoh1相關疾病 | |
JP6188686B2 (ja) | フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療 | |
TWI623317B (zh) | 以針對胚盤大同源物(dlg)之天然反義轉錄本之抑制作用治療dlg相關疾病 | |
JP2018082703A (ja) | ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療 | |
TWI573871B (zh) | 藉由抑制nanog之天然反義轉錄物治療nanog相關疾病 | |
JP6083735B2 (ja) | インスリン受容体基質2(irs2)および転写因子3(tfe3)に対する天然アンチセンス転写物の阻害によるインスリン受容体基質2(irs2)関連疾患の治療 | |
TWI645036B (zh) | 藉由抑制唾液酸酶4(neu4)之天然反義轉錄物以治療neu4相關疾病 | |
TWI575068B (zh) | 藉由抑制msra天然反股轉錄本治療甲硫胺亞磺酸還原酶a(msra)相關疾病 | |
TW201305335A (zh) | 藉由抑制干擾素相關發育調節子1(ifrd1)之天然反義轉錄本治療ifrd1相關疾病 | |
WO2011146674A2 (en) | Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11 | |
TWI734935B (zh) | 上調電壓門控鈉離子通道第I型α次單元(SCN1A)之表現及/或功能之反義寡核苷酸及其用途 | |
RU2575608C2 (ru) | Лечение заболеваний, связанных с белком апоптозного ответа простаты par4, путем ингибирования природного антисмыслового транскрипта гена par4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |